| [Luobufukebiri Pills improve semen quality and seminal plasma-related biochemical indexes in patients with asthenospermia] 2020 · control group · Patients with asthenospermia; age and sex details not reported | 200 mg | 12 weeks | 103 |
| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · Vitamin E · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 300 mg | 1278 days | 2,830 |
| Does palm oil vitamin E reduce the risk of pregnancy induced hypertension? 2013 · TRF arm · Healthy primigravidae, from early second trimester until delivery | 100 mg | — | 151 |
| Effects on health of dietary supplementation with 100 mg d-alpha-tocopheryl acetate, daily for 6 years 1995 · 100 mg group · Healthy volunteers aged 39 to 56 years | 100 mg | 6 years | 74 |
| Effects of Low-Dose Aspirin Combined with Vitamin E on the Incidence of Intrauterine Growth Restriction and Hemorheological Indexes of Pregnant Women in Patients with Gestational Hypertension 2022 · control group · Pregnant women aged 21–35 with gestational hypertension | 150 mg | — | 67 |
| Effects of Low-Dose Aspirin Combined with Vitamin E on the Incidence of Intrauterine Growth Restriction and Hemorheological Indexes of Pregnant Women in Patients with Gestational Hypertension 2022 · observation group · Pregnant women aged 20–37 with gestational hypertension | 150 mg | — | 67 |
| Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks 1995 · aspirin plus vitamin E · Patients with transient ischemic attacks, minor strokes, or residual ischemic neurologic deficits | 400 mg | 2 years | 52 |
| Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial 2010 · Combination clomiphene citrate and vitamin E group · Infertile men with idiopathic oligoasthenozoospermia | 400 mg | 26 weeks | 30 |
| Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy 2003 · group one · Patients with cancer receiving cisplatin chemotherapy | 300 mg | — | — |
| [Gujing Maisiha Tablets combined with natural vitamin E for the treatment of idiopathic asthenospermia] 2017 · control group · Men aged 21–43 with idiopathic asthenospermia | 200 mg | 90 days | 55 |
| Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial 2012 · Metformin group · People with non-alcoholic fatty liver disease; age and sex not specified | 200 mg | 90 days | 43 |
| Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial 2017 · group B · Patients with differentiated thyroid cancer undergoing postsurgical radioiodine ablation | 200 mg | 5 weeks | 22 |
| Benefits of vitamin E supplementation to Norplant users--in vitro and in vivo studies 2000 · vitamin E · Norplant users with endometrial bleeding and at least 3 months of Norplant exposure; age and sex not further stated | 200 mg | 60 days | — |
| Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis 2000 · vitamin E · Smoking and nonsmoking men and postmenopausal women aged 45–69 years with serum cholesterol ≥5.0 mmol/L | 182 mg | 3 years | — |
| Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E 2008 · 200 mg SF-TRE group · healthy adult males | 200 mg | 60 days | — |
| Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study 2009 · Vitamin E group · Women aged 65 years or older in the cognitive substudy, with cardiovascular disease or at least three coronary risk factors | 201 mg | 3249 days | — |
| Tocotrienol-Enriched Beverage Enhances Psychological Well-Being, Antioxidant Defense, and Genomic Stability in Older Adults: A Randomized Controlled Trial 2025 · Group A (intervention group) · Adults aged 50–70 years in generally good health | 200 mg | 26 weeks | — |
| Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial 1997 · 200 mg/d vitamin E group · Healthy free-living adults aged 65 years or older | 200 mg | 235 days | — |
| The effect of β-carotene on the mortality of male smokers is modified by smoking and by vitamins C and E: evidence against a uniform effect of nutrient 2020 · α-Tocopherol alone (AT) · Male smokers aged 50–69 years who smoked at least 5 cigarettes per day at entry | 50 mg | 2227 days | 14,564 |
| Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) 1996 · alpha-tocopherol 800 IU daily · Patients with angiographically proven coronary atherosclerosis; age and sex not stated | 800 IU | 510 days | 546 |
| Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) 1996 · alpha-tocopherol 400 IU daily · Patients with angiographically proven coronary atherosclerosis; age and sex not stated | 400 IU | 510 days | 489 |
| Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial 2000 · vitamin E · Haemodialysis patients aged 40–75 years with pre-existing cardiovascular disease | 800 IU | 519 days | 97 |
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis 2010 · vitamin E group · Adults without diabetes with biopsy-confirmed nonalcoholic steatohepatitis | 800 IU | 96 weeks | 84 |
| Effects on health of dietary supplementation with 100 mg d-alpha-tocopheryl acetate, daily for 6 years 1995 · 3 mg group · Healthy volunteers aged 39 to 56 years | 3 mg | 6 years | 73 |
| Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial 2023 · vitamin E and selenium placebo · Adults aged 18 years or older with newly diagnosed, pathologically confirmed non-muscle-invasive bladder cancer | 200 IU | 548 days | 71 |
| Efficacy of water-based vitamin E solution versus placebo in the prevention of retinopathy of prematurity in very low birth weight infants: A randomized clinical trial 2021 · Group T (treatment group) · Very low birth weight infants with respiratory distress syndrome | 25 IU | 25 days | 48 |
| Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial 2013 · tocotrienols group · Adults aged 36–74 with ultrasound-proven NAFLD and mild untreated hypercholesterolaemia | 522 mg | 1 year | 43 |
| [Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia] 2014 · control group · Men with idiopathic oligoasthenozoospermia | 300 mg | 90 days | 43 |
| Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study 2023 · δ-tocotrienol group · Adults aged 18–75 with metastatic colorectal adenocarcinoma receiving first-line FOLFOXIRI chemotherapy | 900 mg | 2 years | 35 |
| Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial 2005 · Group I · Patients with cancer treated with cisplatin, paclitaxel, or their combination regimens | 600 mg | — | 16 |
| Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation 2006 · Group I · Patients with cancer undergoing paclitaxel-based chemotherapy | 600 mg | — | 16 |
| A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results 2006 · group I · Patients with cancer scheduled to receive cisplatin-based chemotherapy; age and sex not reported | 600 mg | — | 14 |
| The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers 1999 · alpha-tocopherol (AT) · middle-aged male smokers | 50 mg | — | — |
| Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers 2000 · alpha-tocopherol · Men aged 50 to 69 who smoked cigarettes and had no history of stroke | 50 mg | 6 years | — |
| Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 2000 · alpha tocopherol · Men aged 50–69 who smoked and were included in the high-risk-for-stroke subgroup analysis; subgroup condition included hypertension | 50 mg | 6 years | — |
| Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study 2004 · alpha-tocopherol · men aged 50–69 who smoked | 50 mg | 8 years | — |
| Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA) 1992 · vitamin E group · Patients after successful percutaneous transluminal coronary angioplasty (PTCA) | 1,200 IU | 122 days | — |
| Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial 2005 · vitamin E group · Apparently healthy US women aged at least 45 years | 300 IU | 368 days | — |
| [A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia] 2005 · control group · men with oligoasthenozoospermia | 300 mg | 90 days | — |
| Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial 2007 · alpha-tocopherol only · Male smokers aged 50–69 years, free of cancer at baseline | 50 mg | 2227 days | — |
| A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study 2007 · Vitamin E group · Women aged 40 years or older with a history of cardiovascular disease or at least three cardiovascular risk factors | 300 IU | 3431 days | — |
| Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study 2007 · vitamin E group · Women aged 45 years or older; healthy women, including women with and without prior VTE | 300 IU | 372 days | — |
| Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group 1991 · alpha-tocopherol group · People with mild Parkinsonism | 2,000 IU | 1 year | — |
| Vitamin E supplementation may transiently increase tuberculosis risk in males who smoke heavily and have high dietary vitamin C intake 2008 · Vitamin E · Males aged 50–69 years who smoked at baseline and had no tuberculosis diagnosis before randomisation | 50 mg | 2228 days | — |
| Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk 2009 · vitamin E group · Men aged 50–69 years in southwestern Finland who smoked at least five cigarettes per day | 50 mg | 2228 days | — |
| Modification of the effect of vitamin E supplementation on the mortality of male smokers by age and dietary vitamin C 2009 · vitamin E · men aged 50–69 years who smoked at least 5 cigarettes per day | 50 mg | 8 years | — |
| Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival 2009 · α-tocopherol · Caucasian male smokers aged 50–69 years; prostate cancer cases were analysed in this report | 50 mg | 8 years | — |
| Randomised vitamin E supplementation and risk of chronic lung disease in the Women's Health Study 2011 · Vitamin E group · Female healthcare professionals aged 45 years or older, without major chronic illness at enrolment | 300 IU | 10 years | — |
| Effect of intramuscular vitamin E on mortality and intracranial hemorrhage in neonates of 1000 grams or less 1990 · Control group · Premature neonates weighing 501–1000 g and aged 24 hours or less | 100 mg/kg | 6 days | — |
| Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2011 · vitamin E group · Healthy men at average risk of prostate cancer; age 50 or older for African Americans and 55 or older for others | 400 IU | 2008 days | — |
| Reduced mortality among children in southern India receiving a small weekly dose of vitamin A 1990 · control group · Preschool-age children in southern India | 2.86 mg | 1 year | — |
| Vitamin E supplementation and the risk of heart failure in women 2012 · vitamin E · Women aged 45 years or older, apparently healthy and free of cardiovascular disease and cancer | 300 IU | 373 days | — |
| Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT 2012 · vitamin E · Men aged 50 years or older if Black and 55 years or older otherwise, without prior prostate cancer diagnosis | 400 IU | 6 years | — |
| Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis 2013 · α-tocopherol alone · Finnish male smokers aged 50–69 | 50 mg | 2227 days | — |
| Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2014 · vitamin E · African-American men aged 50 years or older and non-African-American men aged 55 years or older, without specified prostate cancer at enrollment | 400 IU | — | — |
| Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC study 2014 · α-tocopherol · Finnish male smokers aged 50–69 at baseline without self-reported cirrhosis | 50 mg | 2922 days | — |
| Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT 2016 · vitamin E alone · Caucasian men without prostate cancer at baseline, included in the SELECT analysis | 400 IU | — | — |
| Vitamin E administration may decrease the incidence of pneumonia in elderly males 2016 · AT (vitamin E) · Finnish males aged 50–69 at entry who smoked at least 5 cigarettes per day and started smoking at age 21 or older; the analysis subgroup included men who smoked 5–19 cigarettes per day and exercised at leisure at baseline | 50 mg | 8 years | — |
| Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial 2022 · vitamin E assignment · Male physicians; mean age 64 ± 9 years | 200 IU | 10 years | — |
| Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study 1995 · alpha-tocopherol · Male cigarette smokers aged 50–69 years | 50 mg | 8 years | — |
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease 1993 · active tocopherol and deprenyl placebo · Patients with early, otherwise untreated Parkinson's disease | 2,000 IU | 426 days | — |
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease 1993 · both active drugs · Patients with early, otherwise untreated Parkinson's disease | 2,000 IU | 426 days | — |
| Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group 1996 · tocopherol treatment · Untreated patients with Parkinson's disease | 2 g | — | — |
| Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group 1996 · deprenyl and tocopherol treatment · Untreated patients with Parkinson's disease | 2 g | — | — |
| Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial 1996 · alpha tocopherol group · Men aged 50–69 who smoked and were free of known coronary heart disease at baseline | 50 mg | 1716 days | — |
| Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance 1996 · alpha-tocopherol · Men aged 50–69 years who smoked at least five cigarettes daily | 50 mg | 2227 days | — |
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study 1997 · alpha-tocopherol (vitamin E) · Patients with moderately severe Alzheimer's disease; age and sex not stated | 2,000 IU | 2 years | — |
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study 1997 · selegiline and alpha-tocopherol · Patients with moderately severe Alzheimer's disease; age and sex not stated | 2,000 IU | 2 years | — |
| Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial 1998 · alpha-tocopherol · Male smokers aged 50–69 years | 50 mg | 2228 days | — |
| [Gujing Maisiha Tablets combined with natural vitamin E for the treatment of idiopathic asthenospermia] 2017 · treatment group · Men aged 22–44 with idiopathic asthenospermia | 200 mg | 90 days | 65 |
| Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial 2021 · Tocovid group · Adults aged 35–75 with type 2 diabetes mellitus and stable glycaemic control; the study did not require diagnosed diabetic peripheral neuropathy | 400 mg | 1 year | 44 |
| The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial 2020 · Tocovid group · Adults aged 35–75 with type 2 diabetes mellitus and HbA1c of 6% to 9%, with or without diabetic peripheral neuropathy symptoms | 400 mg | 8 weeks | 40 |
| Comparative effectiveness of B and e vitamins with diclofenac in reducing pain due to osteoarthritis of the knee 2015 · Vitamin E group · Adults aged 30–60 with primary knee osteoarthritis; the reported age range in this arm was 30–60 years | 100 mg | 3 weeks | 35 |
| Oral Omega-3 Fatty Acid Supplementation for Laser In Situ Keratomileusis-Associated Dry Eye 2017 · control group · Patients undergoing LASIK | 400 mg | 13 weeks | 30 |
| Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial 2017 · group A · Patients with differentiated thyroid cancer undergoing postsurgical radioiodine ablation | 100 mg | 5 weeks | 23 |
| The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields 2022 · Vitamin E group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis | 100 mg | 90 days | 22 |
| [Photodynamic therapy for age related macular degeneration with and without antioxidants] 2002 · Antioxidants · Adults aged 55 to 86 years with bilateral age-related macular degeneration and neovascular membranes | 200 mg | — | 20 |
| Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children 2008 · Group 3 · Obese children aged 10–17 years with non-alcoholic fatty liver disease | 100 mg | 30 days | 19 |
| Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial 2010 · vitamin E group (group 1) · Patients receiving cisplatin chemotherapy; age and sex not specified. | 400 mg | — | 17 |
| γ-Tocopherol-rich supplementation additively improves vascular endothelial function during smoking cessation 2013 · γ-T-rich supplementation · Otherwise healthy smokers, mean age 22 ± 1 years, quitting smoking | 500 mg | 7 days | 16 |
| A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps 2001 · vitamin E · haemodialysis patients with end-stage renal disease; age and sex not specified | 400 mg | 8 weeks | 15 |
| Efficacy of vitamins C, E, and their combination for treatment of restless legs syndrome in hemodialysis patients: a randomized, double-blind, placebo-controlled trial 2012 · vitamin E (400 mg) and placebo · Hemodialysis patients with restless legs syndrome | 400 mg | 8 weeks | 15 |
| Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial 2017 · group C · Patients with differentiated thyroid cancer undergoing postsurgical radioiodine ablation | 300 mg | 5 weeks | 15 |
| Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial 2016 · group 1 · Patients with solid malignancies starting cisplatin; ages and sex not reported | 400 mg | 90 days | 13 |
| Effect of antioxidant vitamin supplementation on muscle function after eccentric exercise 1993 · vitamin E · physically active young subjects | 400 mg | 4 weeks | 8 |
| Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons 1999 · 100-mg vitamin E group · Healthy, noninstitutionalized adults aged 65–80 years | 100 mg | 26 weeks | — |
| Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis 2000 · combination of vitamins E and C · Smoking and nonsmoking men and postmenopausal women aged 45–69 years with serum cholesterol ≥5.0 mmol/L | 182 mg | 3 years | — |
| Lipid peroxide, beta-carotene and alpha-tocopherol in ischaemic stroke and effect of exogenous vitamin E supplementation on outcome 1997 · vitamin E group · Adults with CT-proven ischemic stroke presenting within 24 hours; ages and sex not specified | 300 mg | 15 days | — |
| Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E 2008 · 100 mg SF-TRE group · healthy adult males | 100 mg | 60 days | — |
| Effect of conjugated linoleic acids, vitamin E and their combination on the clinical outcome of Iranian adults with active rheumatoid arthritis 2009 · group E · Adults with active rheumatoid arthritis | 400 mg | 90 days | — |
| Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients 2012 · TCP supplementation · Adults, including healthy participants and surgical patients; prospective liver-transplantation patients were included | 400 mg | 20 weeks | — |
| Vitamin E supplementation, superoxide dismutase status, and outcome of scaling and root planing in patients with chronic periodontitis: a randomized clinical trial 2014 · Treatment group 2 (TG-2) · Patients with chronic periodontitis; age and sex not reported | 100 mg | 90 days | — |
| Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial 2014 · vitamin C and E group · young men and women undergoing endurance training; age range and health condition not stated | 235 mg | 11 weeks | — |
| Vitamin C and E supplementation blunts increases in total lean body mass in elderly men after strength training 2016 · antioxidant group · Men aged 60–81 years participating in strength training | 235 mg | 12 weeks | — |
| Reduction of disease activity in rheumatoid arthritis by tocotrienol-rich fraction supplementation: a randomized, double-blind, placebo-controlled trial 2025 · Tocotrienol-rich fraction (TRF) group · Adults with moderate-to-severe active rheumatoid arthritis | 400 mg | 26 weeks | — |
| Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina 1998 · vitamin E · Patients with coronary spastic angina; age and sex not specified | 300 mg | 30 days | — |
| Prenatal vitamin C and E supplementation in smokers is associated with reduced placental abruption and preterm birth: a secondary analysis 2015 · Vitamin C and E supplementation · Pregnant low-risk nulliparous women with singleton gestations; the reported subgroup analysis included women who smoked during pregnancy | 400 IU | — | 4,993 |
| Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trial 2010 · vitamin C and E supplementation · Low-risk nulliparous women with singleton pregnancies, enrolled at 9 weeks 0 days to 16 weeks 6 days of gestation | 400 IU | — | 4,992 |
| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · n-3 PUFA and vitamin E · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 300 mg | 1278 days | 2,830 |
| Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial 2004 · E group · Nursing home residents aged 65 years or older; no specific diagnosed condition required | 200 IU | 1 year | 311 |
| Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori 2012 · Group A · Patients with Helicobacter pylori infection | 400 IU | 30 days | 160 |
| Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori 2012 · Group A · Patients with Helicobacter pylori infection | 400 IU | 30 days | 160 |
| Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial 1999 · vitamin group · Women at increased risk of pre-eclampsia, enrolled at 16–22 weeks’ gestation | 400 IU | — | 141 |
| CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study 2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye | 6 mg | 3 years | 127 |
| A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement 2013 · supplemented group · Patients scheduled for on-pump cardiac surgery; age and sex not specified | 400 IU | — | 103 |
| Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? 2009 · group B · Patients with Helicobacter pylori infection; age range and sex not reported | 400 IU | 30 days | 80 |
| Efficacy of vitamins supplementation to therapy on Helicobacter pylori eradication in patients with low antioxidant capacity 2011 · Group A · Patients with H. pylori-positive nonulcer dyspepsia, chronic stress, and low total antioxidant capacity | 400 IU | 30 days | 80 |
| Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial 2023 · selenium and vitamin E · Adults aged 18 years or older with newly diagnosed, pathologically confirmed non-muscle-invasive bladder cancer | 200 IU | 548 days | 69 |
| Role of vitamin E and D(3) supplementation in Intra-Cytoplasmic Sperm Injection outcomes of women with polycystic ovarian syndrome: A double blinded randomized placebo-controlled trial 2017 · treatment group · Infertile women with PCOS scheduled for ICSI; age and sex beyond women not specified | 400 mg | 8 weeks | 52 |
| Beneficial effect of l-arginine in women using assisted reproductive technologies: a small-scale randomized controlled trial 2020 · AS2000 group · Women aged under 40 undergoing assisted reproductive technology treatment and planning egg retrieval for embryo transfer | 10 mg | 90 days | 36 |
| [Alcohol-induced toxic hepatitis--a "free radical" associated disease. Lowering fatality by adjuvant antioxidant therapy] 1993 · antioxidant group · Patients with acute alcohol-toxic hepatitis, clinical Child/Pugh severity grades B and C; age and sex not reported | 600 mg | — | 31 |
| Recombinant human erythropoietin in the treatment of anemia of prematurity 1995 · Group A · Premature infants with birthweight ≤1.75 kg, gestational age ≤33 weeks, and anemia (hemoglobin <10 g/dL and hematocrit <30%) | 5 mg/kg | 4 weeks | 26 |
| Recombinant human erythropoietin in the treatment of anemia of prematurity 1995 · Group B · Premature infants with birthweight ≤1.75 kg, gestational age ≤33 weeks, and anemia (hemoglobin <10 g/dL and hematocrit <30%) | 5 mg/kg | 4 weeks | 25 |
| Recombinant human erythropoietin in the treatment of anemia of prematurity 1995 · Group C · Premature infants with birthweight ≤1.75 kg, gestational age ≤33 weeks, and anemia (hemoglobin <10 g/dL and hematocrit <30%) | 5 mg/kg | 4 weeks | 19 |
| Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial 1999 · group C · Interferon-naive patients with chronic hepatitis C; age and sex not reported | 544 IU | 24 weeks | 8 |
| MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience 1999 · antioxidant vitamin supplement · Men and women aged 40–80 at elevated risk of coronary heart disease death due to prior coronary heart disease, occlusive non-coronary arterial disease, diabetes mellitus, or treated hypertension | 600 mg | 5 years | — |
| The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers 1999 · both AT and BC · middle-aged male smokers | 50 mg | — | — |
| Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers 2000 · alpha-tocopherol and beta-carotene · Men aged 50 to 69 who smoked cigarettes and had no history of stroke | 50 mg | 6 years | — |
| Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 2000 · alpha tocopherol and beta carotene · Men aged 50–69 who smoked and were included in the high-risk-for-stroke subgroup analysis | 50 mg | 6 years | — |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 400 IU | 8 years | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants alone · Adults aged 55–81 years with age-related macular degeneration categories 1–4 or other AREDS ocular eligibility; participants in AMD categories 2–4 were eligible for this arm, and category 1 participants could also receive antioxidants | 400 IU | 339 weeks | — |
| Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study 2004 · alpha-tocopherol plus beta-carotene · men aged 50–69 who smoked | 50 mg | 8 years | — |
| Vitamins C and E in the latency period in women with preterm premature rupture of membranes 2005 · vitamin C and vitamin E · Women with singleton pregnancies at 26 to 34 weeks' gestation and PPROM | 400 IU | — | — |
| Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial 2005 · antioxidant vitamins · Adults with acute myocardial infarction; mean age 62 years | 600 mg | 30 days | — |
| Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients 2006 · supplement arm · Head and neck cancer patients treated by radiation therapy | 400 IU | — | — |
| Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial 2007 · alpha-tocopherol plus beta-carotene · Male smokers aged 50–69 years, free of cancer at baseline | 50 mg | 2227 days | — |
| Vitamin E supplementation may transiently increase tuberculosis risk in males who smoke heavily and have high dietary vitamin C intake 2008 · Vitamin E and beta-carotene · Males aged 50–69 years who smoked at baseline and had no tuberculosis diagnosis before randomisation | 50 mg | 2228 days | — |
| Modification of the effect of vitamin E supplementation on the mortality of male smokers by age and dietary vitamin C 2009 · vitamin E + β-carotene · men aged 50–69 years who smoked at least 5 cigarettes per day | 50 mg | 8 years | — |
| Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial 2009 · Factor D · Adults in Linxian, China; age and sex details not given | 30 mg | 313 weeks | — |
| Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival 2009 · α-tocopherol and β-carotene · Caucasian male smokers aged 50–69 years; prostate cancer cases were analysed in this report | 50 mg | 8 years | — |
| Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial 2011 · daily combination of atorvastatin, vitamin C, and vitamin E · Men and women aged 50–70 years; healthy individuals, including a subgroup with NAFLD at baseline | 1,000 IU | 1314 days | — |
| Effect of intramuscular vitamin E on mortality and intracranial hemorrhage in neonates of 1000 grams or less 1990 · Treatment group · Premature neonates weighing 501–1000 g and aged 24 hours or less | 100 mg/kg | 6 days | — |
| Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2011 · selenium plus vitamin E group · Healthy men at average risk of prostate cancer; age 50 or older for African Americans and 55 or older for others | 400 IU | 2008 days | — |
| Reduced mortality among children in southern India receiving a small weekly dose of vitamin A 1990 · treated group · Preschool-age children in southern India | 2.86 mg | 1 year | — |
| Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT 2012 · selenium plus vitamin E · Men aged 50 years or older if Black and 55 years or older otherwise, without prior prostate cancer diagnosis | 400 IU | 6 years | — |
| Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis 2013 · combined β-carotene/α-tocopherol · Finnish male smokers aged 50–69 | 50 mg | 2227 days | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 400 IU | 339 weeks | — |
| Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2014 · selenium plus vitamin E · African-American men aged 50 years or older and non-African-American men aged 55 years or older, without specified prostate cancer at enrollment | 400 IU | — | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 400 IU | 9 years | — |
| Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC study 2014 · α-tocopherol and β-carotene · Finnish male smokers aged 50–69 at baseline without self-reported cirrhosis | 50 mg | 2922 days | — |
| Vitamin E administration may decrease the incidence of pneumonia in elderly males 2016 · AT + BC (vitamin E + β-carotene) · Finnish males aged 50–69 at entry who smoked at least 5 cigarettes per day and started smoking at age 21 or older; the analysis subgroup included men who smoked 5–19 cigarettes per day and exercised at leisure at baseline | 50 mg | 8 years | — |
| The effect of β-carotene on the mortality of male smokers is modified by smoking and by vitamins C and E: evidence against a uniform effect of nutrient 2020 · α-Tocopherol and β-carotene (AT + BC) · Male smokers aged 50–69 years who smoked at least 5 cigarettes per day at entry | 50 mg | 2227 days | — |
| Investigating the preventive effect of vitamins C and E on preeclampsia in nulliparous pregnant women 2020 · intervention group · Nulliparous pregnant women aged 18–38 years without risk factors for preeclampsia | 400 IU | — | — |
| Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study 1995 · beta-carotene and alpha-tocopherol · Male cigarette smokers aged 50–69 years | 50 mg | 8 years | — |
| Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study 1994 · rHuEpo group · Preterm infants up to 32 weeks’ gestation, 2 to 8 weeks postnatal age, with central hematocrit ≤35% and anemia of prematurity | 25 IU | 6 weeks | — |
| Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study 1994 · Placebo group · Preterm infants up to 32 weeks’ gestation, 2 to 8 weeks postnatal age, with central hematocrit ≤35% and anemia of prematurity | 25 IU | 6 weeks | — |
| Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer 1993 · retinol, beta-carotene, and vitamin E · Men aged 50–69 with oral leukoplakia and/or chronic esophagitis | 11.4 mg | 87 weeks | — |
| Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Colorectal Cancer Study Group of the University of Modena and the Health Care District 16 1993 · Group 1 (vitamins) · Individuals after endoscopic polypectomy; age and sex not reported; adenomas were the condition of interest. | 70 mg | 548 days | — |
| Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial 1996 · alpha tocopherol plus beta carotene group · Men aged 50–69 who smoked and were free of known coronary heart disease at baseline | 50 mg | 1716 days | — |
| Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance 1996 · alpha-tocopherol and beta-carotene · Men aged 50–69 years who smoked at least five cigarettes daily | 50 mg | 2227 days | — |
| Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial 1997 · vitamins · Institutionalized elderly subjects in a geriatric center; low serum vitamin C was common at baseline | 15 mg | 2 years | — |
| Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial 1998 · alpha-tocopherol plus beta-carotene · Male smokers aged 50–69 years | 50 mg | 2228 days | — |
| A randomized controlled trial of vitamin E and selenium on rate of decline in lung function 2015 · Vitamin E · Men aged 50 years and older without clinical evidence of prostate cancer | 400 IU | 5 years | 726 |
| Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid 1998 · alpha-tocopherol supplementation · Male smokers aged 55–74 years | 50 mg | 6 years | 191 |
| Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial 2014 · alpha tocopherol plus memantine · Veterans with mild to moderate Alzheimer disease taking an acetylcholinesterase inhibitor; mean age 78.8 years, 97% men | 2,000 IU | 4 years | 154 |
| Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial 2014 · alpha tocopherol alone · Veterans with mild to moderate Alzheimer disease taking an acetylcholinesterase inhibitor; mean age 78.8 years, 97% men | 2,000 IU | 4 years | 152 |
| Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis 2019 · Vitamin E group, adults in PIVENS · Adults with biopsy-proven NASH, without diabetes or cirrhosis | 800 IU | 96 weeks | 69 |
| The effect of vitamin E on hot flashes in menopausal women 2007 · vitamin E therapy · Menopausal women with hot flashes | 400 IU | 4 weeks | 51 |
| Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels 2002 · VE group · People with atopic dermatitis; age and sex distribution not fully specified | 400 IU | 240 days | 50 |
| Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis 2019 · Vitamin E group, children in TONIC · Children with NAFLD, without diabetes | 800 IU | 96 weeks | 48 |
| Evaluation of the effect of vitamin E on pelvic pain reduction in women suffering from primary dysmenorrhea 2013 · study group · Women with primary dysmenorrhea | 400 IU | 60 days | 42 |
| [Effectiveness of vitamin E in comparison with diclofenac sodium in treatment of patients with chronic polyarthritis] 1998 · vitamin E group · Hospitalized patients with established chronic rheumatoid arthritis; age and sex not reported | 1.2 g | 3 weeks | 42 |
| δ-Tocotrienol in Combination with Resveratrol Improves the Cardiometabolic Risk Factors and Biomarkers in Patients with Metabolic Syndrome: A Randomized Controlled Trial 2023 · TRM · Adults aged 18–60 years with metabolic syndrome | 500 mg | 24 weeks | 41 |
| Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype 2011 · vitamin E treatment period, Hp 2-1 genotype · Adults with diabetes and the haptoglobin 2-1 genotype | 400 IU | 90 days | 31 |
| Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability 2016 · Group B (Peg-IFNα + RBV + Silybin, vitamin E, phospholipids) · Male and female adults with chronic hepatitis C receiving pegylated interferon-α and ribavirin | 90 mg | 1 year | 31 |
| Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients 2016 · alpha-tocopherol + omega-3 fatty acids placebo · Chronic hemodialysis patients; age and sex not specified | 400 IU | 12 weeks | 30 |
| The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome 2019 · magnesium plus vitamin E supplements · Women aged 18–40 years with polycystic ovary syndrome | 400 mg | 12 weeks | 30 |
| Effects of vitamins C and E supplementation combined with 12-week resistance training in older women with sarcopenia: A randomized, double-blind, placebo-controlled trial 2025 · Antioxidant supplementation group (AS) · Women aged 60–75 with sarcopenia; all participants had inadequate baseline vitamin C status, and most had inadequate vitamin E status. | 335 mg | 12 weeks | 30 |
| Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype 2011 · vitamin E treatment period, Hp 2-2 genotype · Adults with diabetes and the haptoglobin 2-2 genotype | 400 IU | 90 days | 28 |
| [High dosage vitamin E therapy in patients with activated arthrosis] 1990 · Vitamin E (V) · In-patients with osteoarthritis of the hip or knee | 1.2 g | 3 weeks | 26 |
| Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial 2018 · vitamin E · University students with primary dysmenorrhea | 200 IU | — | 25 |
| Effect of vitamin E with and without saffron on the sexual function in women of reproductive age with sexual dysfunction: a randomized controlled trial 2024 · Vitamin E + placebo of saffron (control group) · Women aged 15–49 with sexual dysfunction and without severe or very severe depression or sleep disorders | 50 mg | 8 weeks | 25 |
| Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease 2003 · Vitamin E plus colchicine group · Patients aged 40–62 with early Peyronie's disease, penile deformity under 30 degrees, and no erectile dysfunction | 600 mg | 26 weeks | 23 |
| Gamma tocopherol effect on LPS-induced sputum neutrophilia is not modified by BMI or GSTM1 genotype 2019 · γT-enriched supplement · Adults with mild asthma, not using daily inhaled controller therapies; sex and age range not specified | 1.2 g | 2 weeks | 23 |
| The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial 2004 · vitamin E · Chinese inpatients with tardive dyskinesia | 1,200 IU | 12 weeks | 22 |
| Double-blind intervention trial on modulation of ozone effects on pulmonary function by antioxidant supplements 1999 · vitamin group · Dutch bicyclists; adults, with no stated medical condition, studied during exercise in ozone exposure | 100 mg | 15 weeks | 20 |
| Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients 2000 · Vit.E treatment · Adults with type II diabetes mellitus, free of diabetic complications; sex and age range not specified | 600 mg | 8 weeks | 20 |
| Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens 1992 · alphatocopherol (vitamin E) · Patients receiving suxamethonium; age and sex not reported | 600 mg | — | 20 |
| Systemic hypoxia enhances bactericidal activities of human polymorphonuclear leuocytes 2009 · vitamin E group · healthy sedentary men | 1,000 IU | 1 day | 20 |
| Water-soluble coenzyme Q10 formulation (Q-TER(®)) in the treatment of presbycusis 2010 · Group B · Patients with presbycusis; age and sex not reported | 50 mg | 30 days | 20 |
| Pharmacological doses of vitamin E and insulin action in elderly subjects 1994 · vitamin E · Elderly adults (mean age 77 years), nonobese, with normal glucose tolerance | 900 mg | 120 days | 20 |
| Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial 1997 · alpha-tocopherol · Patients with rheumatoid arthritis receiving anti-rheumatic drugs; age and sex not stated | 1.2 g | 12 weeks | 20 |
| Vitamin E and immunity after the Kona Triathlon World Championship 2004 · Vitamin E group · Triathletes competing in the Kona Triathlon World Championship; age and sex not reported | 800 IU | 60 days | 19 |
| Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? 2013 · vitamin E group · Patients with differentiated thyroid carcinoma undergoing ¹³¹I treatment | 800 IU | 5 weeks | 19 |
| Gamma tocopherol effect on LPS-induced sputum neutrophilia is not modified by BMI or GSTM1 genotype 2019 · γT-enriched supplement · Healthy volunteers; adults, sex and age range not specified | 1.2 g | 7 days | 18 |
| Vitamin E in the treatment of tardive dyskinesia 1993 · vitamin E group · Patients with tardive dyskinesia; age and sex not reported | 1.2 g | 4 weeks | 17 |
| A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia 1996 · vitamin E group · Patients with tardive dyskinesia; 29 had schizophrenia and 6 had a mood disorder | 1,600 IU | 60 days | 17 |
| A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps 2001 · combination of vitamins E and C · haemodialysis patients with end-stage renal disease; age and sex not specified | 400 mg | 8 weeks | 15 |
| Efficacy of vitamins C, E, and their combination for treatment of restless legs syndrome in hemodialysis patients: a randomized, double-blind, placebo-controlled trial 2012 · vitamin C (200 mg) and vitamin E (400 mg) · Hemodialysis patients with restless legs syndrome | 400 mg | 8 weeks | 15 |
| Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial 2022 · atorvastatin with vitamin E (A+E) group · Women aged 18–65 with type 2 diabetes and hyperlipidemia | 400 IU | 12 weeks | 15 |
| Effect of coenzyme q10 on myopathic symptoms in patients treated with statins 2007 · vitamin E · Patients with statin-associated myopathic symptoms | 400 IU | 30 days | 14 |
| Dialysis leg cramps. Efficacy of quinine versus vitamin E 1992 · vitamin E · Patients on dialysis with a history of leg cramps | 400 IU | 60 days | 13 |
| Effects of vitamin E on chronic and acute endothelial dysfunction in smokers 2000 · vitamin E · healthy male smokers; mean age 28 ± 6 years | 600 IU | 4 weeks | 11 |
| Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis 2011 · group E · Patients with atopic dermatitis; age and sex not specified | 600 IU | 60 days | 11 |
| Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses 1998 · treatment group · Patients with tardive dyskinesia whose medication had been unchanged for at least 1 month | 600 mg | 213 days | 11 |
| Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study 1998 · vitamin E · People with type 2 diabetes and diabetic peripheral sensorimotor polyneuropathy | 900 mg | 26 weeks | 11 |
| Effect of vitamin E supplementation with exercise on cognitive functions and total antioxidant capacity in older people 2010 · V group (vitamin E group) · Sedentary adults aged 60–79 living in a retirement home, without medical illness or significant cognitive impairment | 900 mg | 26 weeks | 10 |
| Effect of vitamin E supplementation with exercise on cognitive functions and total antioxidant capacity in older people 2010 · EV group (vitamin E under training group) · Sedentary adults aged 60–79 living in a retirement home, without medical illness or significant cognitive impairment | 900 mg | 26 weeks | 10 |
| Lack of effect of vitamin E on L-arginine-responsive endothelial dysfunction in patients with mild hypercholesterolaemia and coronary artery disease 1998 · vitamin E · Adults with mild hypercholesterolaemia and angiographically documented coronary artery disease | 400 IU | 8 weeks | 10 |
| Attenuation of angiotensin converting enzyme inhibitor induced cough by iron supplementation: role of nitric oxide 2011 · anti-oxidant group · Patients with cough while receiving ACE-inhibitor therapy; age and sex not reported | 200 mg | 4 weeks | 8 |
| Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels 1999 · alpha-tocopherol group, high remnant lipoprotein levels · Patients with high serum remnant lipoprotein levels | 300 IU | 4 weeks | — |
| Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels 1999 · alpha-tocopherol group, low remnant lipoprotein levels · Patients with low serum remnant lipoprotein levels | 300 IU | 4 weeks | — |
| Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons 1999 · 50-mg vitamin E group · Healthy, noninstitutionalized adults aged 65–80 years | 50 mg | 26 weeks | — |
| High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes 1999 · Vitamin E treatment · People with type 1 diabetes of less than 10 years’ duration and nondiabetic control subjects; ages and sex not stated | 1,800 IU | 120 days | — |
| The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial 1999 · alpha-tocopherol only · Male smokers aged 50–69 with intermittent claudication | 50 mg | 193 weeks | — |
| Vascular effects of estrogen and vitamin E therapies in postmenopausal women 1999 · vitamin E · healthy postmenopausal women | 800 IU | 6 weeks | — |
| Vascular effects of estrogen and vitamin E therapies in postmenopausal women 1999 · conjugated equine estrogens plus vitamin E · healthy postmenopausal women | 800 IU | 6 weeks | — |
| Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study 2000 · vitamin E therapy · Young subjects with type I diabetes mellitus | 1,000 IU | 90 days | — |
| Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes 2001 · vitamin E · Patients with type 2 diabetes and cardiac autonomic neuropathy; age and sex not reported. | 600 mg | 120 days | — |
| A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group 2001 · alpha-tocopherol group · Adults with ALS of less than 5 years' duration, treated with riluzole; age and sex not specified | 1 g | 1 year | — |
| UVB photoprotection with antioxidants: effects of oral therapy with d-alpha-tocopherol and ascorbic acid on the minimal erythema dose 2002 · Group 1 · Healthy volunteers | 1,200 IU | 7 days | — |
| Physical activity and the common cold in men administered vitamin E and beta-carotene 2003 · Vitamin E only · Men aged 50–69 who smoked; common-cold risk was assessed in physically active subgroups | 50 mg | 2227 days | — |
| Effect of vitamin E supplementation on the regular treatment of seasonal allergic rhinitis 2004 · vitamin E · Patients with documented hay fever (seasonal allergic rhinitis) | 800 mg | — | — |
| Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma 2005 · Antioxidants in addition to standard antiasthmatic therapy · Adults aged 25–50 with persistent mild to moderate bronchial asthma | 400 mg | 16 weeks | — |
| Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E 2008 · 50 mg SF-TRE group · healthy adult males | 50 mg | 60 days | — |
| Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study 2010 · vitamin E · Women with premenstrual cyclical breast discomfort | 1,200 IU | 26 weeks | — |
| Effect of conjugated linoleic acids, vitamin E and their combination on the clinical outcome of Iranian adults with active rheumatoid arthritis 2009 · group CE · Adults with active rheumatoid arthritis | 400 mg | 90 days | — |
| Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects 1990 · vitamin E-supplemented group · healthy older adults; sex and exact age range not reported | 800 mg | 30 days | — |
| Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase 2013 · vitamin E group · Patients with erectile dysfunction initially irresponsive to sildenafil; age and sex details not stated | 400 IU | 6 weeks | — |
| The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial 2014 · antioxidant supplementation · Adults aged 60–75 years with mild cognitive impairment | 300 mg | 1 year | — |
| Vitamin e supplementation, lung functions and clinical manifestations in children with moderate asthma: a randomized double blind placebo- controlled trial 2014 · case group · Children aged 5–17 years with moderate asthma | 50 mg | 8 weeks | — |
| Efficacy of supplementary vitamins C and E on anxiety, depression and stress in type 2 diabetic patients: a randomized, single-blind, placebo-controlled trial 2013 · vitamin E group · Adults with type 2 diabetes; age and sex not specified | 400 IU | 6 weeks | — |
| Short term effects of palm-tocotrienol and palm-carotenes on vascular function and cardiovascular disease risk: A randomised controlled trial 2016 · TRF-80 · Men and women aged 18–70 years with type 2 diabetes, impaired fasting glucose and/or elevated waist circumference, at increased risk of impaired vascular function | 552 mg | 8 weeks | — |
| The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: A triple blind randomised controlled trial 2020 · vitamin E group · Postmenopausal women; mean age 51.7 years | 200 IU | 8 weeks | — |
| Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial 2020 · EP group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function | 600 IU | 12 weeks | — |
| Curcumin and vitamin E improve hot flashes, lipid profile, and fasting blood glucose without any detrimental effect on the liver and renal function in postmenopausal women: A triple-blind placebo-controlled clinical trial 2024 · Vitamin E group · Postmenopausal women | 400 IU | 8 weeks | — |
| Randomized Clinical Trial of Antioxidant Therapy Patients with Septic Shock and Organ Dysfunction in the ICU: SOFA Score Reduction by Improvement of the Enzymatic and Non-Enzymatic Antioxidant System 2023 · Group 2 (Vit E) · Adults older than 18 years of any gender with septic shock admitted to the ICU | 1,200 IU | 5 days | — |
| Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects 2023 · Group 2 (Vit E) · Adults over 18 years of any gender with septic shock | 1,200 IU | 5 days | — |
| "Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single blind, controlled trial" 2025 · control group · Patients with grade 1 (mild) or grade 2 (moderate) non-alcoholic fatty liver disease; ages and sex not reported | 800 mg | 60 days | — |
| Effect of vitamin E supplementation on recovery and recurrence prevention in women with lower urinary tract infections: A triple-blind randomized clinical trial 2026 · intervention group · Women over 18 years old with lower urinary tract infection | 100 IU | 26 weeks | — |
| A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility 1995 · Vitamin E (order A) · Men with high levels of reactive oxygen species generation in semen and a normal female partner | 600 mg | 90 days | — |
| The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group 1994 · tocopherol · patients with early untreated Parkinson's disease | 2,000 IU | 426 days | — |
| The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group 1994 · deprenyl and tocopherol · patients with early untreated Parkinson's disease | 2,000 IU | 426 days | — |
| Vitamin E treatment of tardive dyskinesia 1993 · Vitamin E · Patients with tardive dyskinesia | 1,600 IU | 12 weeks | — |
| A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa 1993 · Vitamin E · Patients aged 18 through 49 years with retinitis pigmentosa | 400 IU | 6 years | — |
| Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial 1997 · 60 mg/d vitamin E group · Healthy free-living adults aged 65 years or older | 60 mg | 235 days | — |
| Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial 1997 · 800 mg/d vitamin E group · Healthy free-living adults aged 65 years or older | 800 mg | 235 days | — |
| Prospective evaluation of vitamin E for hot flashes in breast cancer survivors 1998 · vitamin E phase · Breast cancer survivors; age and sex not specified | 800 IU | 4 weeks | — |
| [Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance] 1998 · vitamin E group · Normal volunteers and patients with ischemic heart disease; age and sex not reported | 600 mg | 6 days | — |
| Long-term treatment effects of vitamin E for tardive dyskinesia 1998 · d-vitamin E · Patients with tardive dyskinesia on stable oral medications | 1,600 IU | 36 weeks | — |
| High doses of vitamin C plus E reduce strength training-induced improvements in areal bone mineral density in elderly men 2017 · antioxidant group (AO) · Healthy elderly men; age range not reported (mean age 70 ± 7 years) | 235 mg | 12 weeks | 16 |
| The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial 2007 · RRR-alpha-tocopherol · Individuals with type 2 diabetes; age and sex not specified | 500 mg | 6 weeks | — |
| The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial 2007 · mixed tocopherols · Individuals with type 2 diabetes; age and sex not specified | 500 mg | 6 weeks | — |
| Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial 2007 · fortified milk · Children aged 1–3 years in a peri-urban settlement in north India | 7.5 mg | 1 year | 316 |
| Antioxidant supplement and long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized trial 2013 · active compound · Patients who had undergone polypectomy and were undergoing post-polypectomy endoscopic follow-up | 30 mg | 5 years | 164 |
| Effects of perioperative vitamin E and zinc co-supplementation on systemic inflammation and length of stay following coronary artery bypass graft surgery: a randomized controlled trial 2024 · intervention group · Patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass; age and sex not reported | 200 IU | 3 weeks | 40 |
| Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly 2004 · special nutritional formula · Healthy adults aged 70 years or older with Mini Mental score ≥22 | 120 IU | 1 year | 30 |
| "The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. SUpplementation on VItamines et Minéraux AntioXydants 1999 · antioxidant vitamins and minerals supplementation · Women aged 35 to 60 years and men aged 45 to 60 years, without a stated condition | 30 mg | 8 years | — |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 400 IU | 8 years | — |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 8 mg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 10 mg | — | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants plus zinc · Adults aged 55–81 years with AMD categories 2–4 and AREDS ocular eligibility | 400 IU | 339 weeks | — |
| The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals 2004 · antioxidant supplement group · French women aged 35–60 and men aged 45–60 in the general population | 30 mg | 2739 days | — |
| Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? 2005 · daily antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 30 mg | 2739 days | — |
| [The SU.VI.MAX study, a randomized, placebo-controlled trial on the effects of antioxidant vitamins and minerals on health] 2006 · antioxidant supplementation · Middle-aged adults in the general population | 30 mg | 2738 days | — |
| Antioxidant supplementation increases the risk of skin cancers in women but not in men 2007 · antioxidant group · French adult women and men in a general-population primary-prevention trial | 30 mg | 2738 days | — |
| Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study 2010 · antioxidant supplementation · French women aged 35–60 years and men aged 45–60 years | 30 mg | 2738 days | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 400 IU | 339 weeks | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 400 IU | 9 years | — |
| Supplementation with multivitamins and vitamin A and incidence of malaria among HIV-infected Tanzanian women 2014 · multivitamins without vitamin A · HIV-infected pregnant women in Tanzania | 30 mg | 1249 days | — |
| Supplementation with multivitamins and vitamin A and incidence of malaria among HIV-infected Tanzanian women 2014 · multivitamins with vitamin A · HIV-infected pregnant women in Tanzania | 30 mg | 1249 days | — |
| Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer 1993 · riboflavin plus retinol, beta-carotene, and vitamin E · Men aged 50–69 with oral leukoplakia and/or chronic esophagitis | 11.4 mg | 87 weeks | — |
| Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial 1997 · combination of trace elements and vitamins · Institutionalized elderly subjects in a geriatric center; low serum vitamin C, zinc and selenium were common at baseline | 15 mg | 2 years | — |
| Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants 1998 · active medication · Adults with colorectal polyps; age range and sex not stated | 75 mg | 3 years | — |
| Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial 2015 · supplemented group · Adults with facioscapulohumeral muscular dystrophy (FSHD) | 400 mg | 17 weeks | 26 |
| A randomized controlled trial of vitamin E and selenium on rate of decline in lung function 2015 · Vitamin E and Selenium · Men aged 50 years and older without clinical evidence of prostate cancer | 400 IU | 5 years | 709 |
| Sesame Lignans and Vitamin E Supplementation Improve Subjective Statuses and Anti-Oxidative Capacity in Healthy Humans With Feelings of Daily Fatigue 2015 · SVE group · Healthy men and women aged 30–69 who reported daily fatigue | 55 mg | 8 weeks | 154 |
| Antioxidant supplementation reduces endometriosis-related pelvic pain in humans 2013 · Group A · Women aged 19–41 with pelvic pain and a history of endometriosis and/or infertility | 1,200 IU | 8 weeks | 46 |
| Single dose vitamin A treatment in acute shigellosis in Bangladesh children: randomised double blind controlled trial 1998 · Vitamin A group · Children aged 1–7 years with bacteriologically proven acute shigellosis and no clinical signs of vitamin A deficiency | 25 IU | 1 day | 42 |
| Effects of antioxidant vitamins C and E on signal-averaged electrocardiogram in acute myocardial infarction 1996 · supplemented group · Patients with acute myocardial infarction | 600 mg | 2 weeks | 33 |
| Does vitamin C or its combination with vitamin E improve radial artery endothelium-dependent vasodilatation in patients awaiting coronary artery bypass surgery? 2013 · vitamins C + E group (group 2) · Adults with angiographically confirmed significant coronary artery disease awaiting coronary artery bypass surgery | 600 IU | 1 day | 31 |
| Vitamin E and ginseng supplementation to enhance female sexual function: a randomized, double-blind, placebo-controlled, clinical trial 2020 · supplement group · Women with sexual dysfunction, age range not reported | 100 IU | 6 weeks | 31 |
| Acute autonomic effects of vitamins and fats in male smokers 2009 · moderate vitamins · Male smokers, mean age 34.2 years (SD 6.9) | 75 IU | 1 day | 30 |
| Acute autonomic effects of vitamins and fats in male smokers 2009 · high doses of vitamins · Male smokers, mean age 34.2 years (SD 6.9) | 800 IU | 1 day | 30 |
| Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients 2016 · omega-3 fatty acids + vitamin E · Chronic hemodialysis patients; age and sex not specified | 400 IU | 12 weeks | 30 |
| Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients 2016 · omega-3 fatty acids + alpha-tocopherol · Chronic hemodialysis patients; age and sex not specified | 400 IU | 12 weeks | 30 |
| The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial 2019 · magnesium plus vitamin E · Patients with grade 3 diabetic foot ulcer | 400 IU | 12 weeks | 29 |
| Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter 2013 · PTX and vitamin E treatment · Breast cancer patients with localized disease after breast/chest wall irradiation | 400 IU | 26 weeks | 26 |
| Randomized Trial of Vitamin C/E Complex for Prevention of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer 2016 · trial group · Patients with head and neck cancer receiving radiotherapy; age and sex not reported | 200 IU | — | 25 |
| Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial 2018 · vitamin E-omega-3 · University students with primary dysmenorrhea | 200 IU | — | 25 |
| Effect of vitamin E with and without saffron on the sexual function in women of reproductive age with sexual dysfunction: a randomized controlled trial 2024 · Saffron + Vitamin E (experimental group) · Women aged 15–49 with sexual dysfunction and without severe or very severe depression or sleep disorders | 50 mg | 8 weeks | 25 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea | 1.5 mg | 60 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea | 1.5 mg | 60 days | 21 |
| A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy 2001 · vitamin treated group · patients who underwent myopic photorefractive keratectomy (PRK); age and sex not reported | 230 mg | 360 days | 20 |
| Protective effect of anti-oxidants on endothelial function in young Korean-Asians compared to Caucasians 2012 · antioxidant vitamins · Healthy Korean and Caucasian adults aged 20–35 years | 800 IU | 2 weeks | 20 |
| The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome 2018 · omega-3 fatty acids plus vitamin E · Women with polycystic ovary syndrome (PCOS) | 400 IU | 12 weeks | 20 |
| Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal 1997 · high-fat meal with vitamins · Healthy, normocholesterolemic men and women aged 24 to 54 years | 800 IU | 1 day | 20 |
| [Analysis on therapeutic effect of variable-frequency electroacupuncture combined with herbal-moxa moxibustion for post-zoster neuralgia] 2012 · medication group · Adults with herpes zoster regional neuralgia | 200 mg | 7 days | 19 |
| The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields 2022 · Vitamin E + Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis | 100 mg | 90 days | 19 |
| Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers 2013 · γT-enriched supplement · Healthy volunteers with negative methacholine challenge | 1.66 g | 7 days | 17 |
| Impairment of coronary circulation by acute hyperhomocysteinaemia and reversal by antioxidant vitamins 2004 · methionine load with antioxidant vitamins · Healthy volunteers aged 26–40 years; nine men and seven women, with no stated condition | 800 IU | 1 day | 16 |
| Effect of strength training combined with antioxidant supplementation on muscular performance 2018 · vitamins · Women, mean age 23.8 years, participating in strength training; no diagnosed condition stated | 400 IU | 10 weeks | 15 |
| Improved lung function following dietary antioxidant supplementation in exercise-induced asthmatics 2016 · Vitamins (V) · Adults with exercise-induced asthma (mean age 22.0 years) and healthy controls (mean age 28.2 years) | 300 IU | 3 weeks | 13 |
| Acute effects of ozone on pulmonary function of cyclists receiving antioxidant supplements 1998 · supplementation group · Amateur cyclists; age and sex not reported; no condition stated | 75 mg | 90 days | 12 |
| Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis 2011 · group DE · Patients with atopic dermatitis; age and sex not specified | 600 IU | 60 days | 11 |
| Green tea and vitamin E enhance exercise-induced benefits in body composition, glucose homeostasis, and antioxidant status in elderly men and women 2013 · GTVE · Healthy elderly men and women; mean age 71.1 years | 400 IU | 12 weeks | 11 |
| Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal 1997 · low-fat meal with vitamins · A subgroup of healthy, normocholesterolemic men and women aged 24 to 54 years | 800 IU | 1 day | 10 |
| Effect of vitamin supplementation on lung injury and running performance in a hot, humid, and ozone-polluted environment 2011 · Vitamin trial · Runners; age, sex, and health condition not specified | 100 IU | 2 weeks | 9 |
| The effects of acute oral antioxidants on diving-induced alterations in human cardiovascular function 2007 · acute antioxidants · Experienced divers; age and sex not reported | 400 IU | 1 day | 6 |
| Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis 2011 · Subgroup A · Patients with early diffuse systemic sclerosis, positive anti-topoisomerase-I antibody, high skin thickening progression rate and decreased lung diffusing capacity; age and sex not reported | 400 IU | 26 weeks | 6 |
| The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial 1999 · alpha-tocopherol plus beta-carotene · Male smokers aged 50–69 with intermittent claudication | 50 mg | 193 weeks | — |
| Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans 2000 · Carotenoid supplement plus vitamin E · Healthy volunteers | 335 mg | 12 weeks | — |
| The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract 2002 · vitamin group · Adult American and English outpatients with early age-related cataract | 600 mg | 3 years | — |
| UVB photoprotection with antioxidants: effects of oral therapy with d-alpha-tocopherol and ascorbic acid on the minimal erythema dose 2002 · Group 3 · Healthy volunteers | 1,200 IU | 7 days | — |
| Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants 2002 · vitamin supplement group · Children with asthma living in Mexico City; age and asthma severity not specified | 50 mg | — | — |
| Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study 2003 · supplemented group · Men and postmenopausal women aged 45–69 years, smoking or nonsmoking, with serum cholesterol ≥5.0 mmol/L | 272 IU | 6 years | — |
| Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus 2003 · oral antioxidant therapy · People with Type 1 or Type 2 diabetes and matched healthy control subjects; ages and sex not reported | 800 IU | 26 weeks | — |
| Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial 2003 · antioxidant vitamin therapy · children with familial hypercholesterolemia or the phenotype of familial combined hyperlipidemia | 400 IU | 6 weeks | — |
| Physical activity and the common cold in men administered vitamin E and beta-carotene 2003 · Vitamin E and beta-carotene · Men aged 50–69 who smoked; common-cold risk was assessed in physically active subgroups | 50 mg | 2227 days | — |
| Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis 2003 · vitamins E and C · Patients with nonalcoholic steatohepatitis (NASH); age and sex not specified | 1,000 IU | 26 weeks | — |
| Effects of dietary supplementation with vitamins C and E on muscle function during and after eccentric contractions in humans 2004 · treatment group · male volunteers; no age range or diagnosed condition reported | 1,200 IU | 37 days | — |
| Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients 2005 · supplement arm · Head and neck cancer patients receiving radiation therapy; age and sex not stated | 400 IU | 3 years | — |
| Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients 2009 · EP1 · Patients with severe erythrodermic psoriasis | 50 mg | 30 days | — |
| Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients 2009 · PsA1 · Patients with severe arthropathic psoriasis | 50 mg | 5 weeks | — |
| Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study 2010 · vitamin E plus EPO · Women with premenstrual cyclical breast discomfort | 1,200 IU | 26 weeks | — |
| Improvement of major depression is associated with increased erythrocyte DHA 2013 · HiDHA · Adults receiving treatment for major depression | 10 mg | 16 weeks | — |
| Antioxidants improve vascular function in children conceived by assisted reproductive technologies: A randomized double-blind placebo-controlled trial 2015 · Antioxidant vitamins · Children conceived by assisted reproductive technology (ART) | 400 IU | 4 weeks | — |
| Antioxidants improve vascular function in children conceived by assisted reproductive technologies: A randomized double-blind placebo-controlled trial 2015 · Antioxidant vitamins · Control children (children not conceived by assisted reproductive technology) | 400 IU | 4 weeks | — |
| Amelioration of persistent left ventricular function impairment through increased plasma ascorbate levels following myocardial infarction 2016 · HA group (high ascorbate, >1 mmol/l) · Patients of either sex with a first ST-segment elevation myocardial infarction undergoing primary percutaneous coronary angioplasty | 400 IU | 12 weeks | — |
| Amelioration of persistent left ventricular function impairment through increased plasma ascorbate levels following myocardial infarction 2016 · LA group (low ascorbate, <1 mmol/l) · Patients of either sex with a first ST-segment elevation myocardial infarction undergoing primary percutaneous coronary angioplasty | 400 IU | 12 weeks | — |
| Mechanical Ventilation Antioxidant Trial 2015 · vitamin C plus vitamin E · critically ill adults requiring mechanical ventilation | 3,000 IU | — | — |
| Mechanical Ventilation Antioxidant Trial 2015 · vitamin C plus vitamin E plus N-acetylcysteine · critically ill adults requiring mechanical ventilation | 3,000 IU | — | — |
| Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial 2020 · DE group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function | 600 IU | 12 weeks | — |
| An Examination into the Effects of a Nutraceutical Supplement on Cognition, Stress, Eye Health, and Skin Satisfaction in Adults with Self-Reported Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · nutraceutical group · Healthy males and females aged 40–75 with self-reported memory complaints | 12 mg | 12 weeks | — |
| A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa 1993 · Vitamin A plus vitamin E · Patients aged 18 through 49 years with retinitis pigmentosa | 400 IU | 6 years | — |
| Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E) 1998 · vitamins C and E · Human subjects; age, sex, and health status not specified; assessed for sunburn response | 1,000 IU | 8 days | — |
| Antioxidant supplementation and respiratory functions among workers exposed to high levels of ozone 1998 · supplement group · Mexico City street workers exposed to high ozone levels; age and sex not stated | 75 mg | 26 weeks | — |
| Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation 1998 · Group (3) · Healthy volunteers | 2 g | 50 days | — |
| The impact of vitamins and/or mineral supplementation on blood pressure in type 2 diabetes 2004 · group V · People with type 2 diabetes; age and sex not reported | 150 mg | 90 days | 18 |
| Vitamin E can reduce blood pressure in mild hypertensives 2002 · drug group (DG) · Adults aged 20–60 with mild hypertension and no other cardiovascular risk factors | 200 IU | 27 weeks | — |
| Vitamin E differentially affects short term exercise induced changes in oxidative stress, lipids, and inflammatory markers 2012 · vitamin E · Sedentary, otherwise healthy adults: women aged 18–55 and men aged 18–50 | 800 IU | 8 weeks | — |
| Perturbation of cellular immune functions in cigarette smokers and protection by palm oil vitamin E supplementation 2013 · Smokers receiving palmvitee · Healthy male cigarette smokers aged 20–50 years; smoking for at least 5 years and at least 10 cigarettes daily | 200 mg | 24 weeks | 30 |
| Perturbation of cellular immune functions in cigarette smokers and protection by palm oil vitamin E supplementation 2013 · Nonsmokers receiving palmvitee · Healthy male nonsmokers aged 20–50 years | 200 mg | 24 weeks | 29 |
| Effects of gamma-tocopherol supplementation on thrombotic risk factors 2007 · 200 mg/day gamma-T group · Healthy subjects; age and sex not reported | 200 mg | 5 weeks | 13 |
| Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations 1996 · A: RRR-alpha-tocopherol · Patients aged 0.7–29.8 years with cystic fibrosis | 268 mg | 6 weeks | 10 |
| Plasma vitamin C and tocotrienols changes in response to dietary supplementation among young male adults 2010 · Tocotrienol · young male police recruits | 200 mg | 8 weeks | — |
| Effects of dietary supplementation of alpha-tocopherol on plasma glutathione and DNA repair activities 1996 · 200 mg/day alpha-tocopherol group · healthy volunteers; age and sex not stated | 200 mg | 4 weeks | — |
| Micronutrient fortified milk improves iron status, anemia and growth among children 1-4 years: a double masked, randomized, controlled trial 2010 · Micronutrient-fortified milk (MN group) · Children aged 1–4 years in India; many had anemia, iron deficiency, or growth faltering | 7.5 mg | 1 year | 316 |
| Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial 2017 · PCSO-524® · Children and adolescents aged 6–14 years with elevated ADHD symptoms, including participants with and without an ADHD diagnosis | 675 mcg | 14 weeks | 74 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 30 IU | 90 days | 59 |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 1 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 250 mg | 14 weeks | 55 |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 2 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 30 mg | 14 weeks | 55 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 7.6 mg | 12 weeks | 40 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 30 IU | 26 weeks | 38 |
| A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study 2019 · verum group · Women aged 35–73 with healthy skin | 2.3 mg | 12 weeks | 36 |
| Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy 2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years | 15 mg | 26 weeks | 36 |
| Effect of a mixture of micronutrients, but not of bovine colostrum concentrate, on immune function parameters in healthy volunteers: a randomized placebo-controlled study 2006 · Colostrum + Micronutrients · Healthy, non-smoking men and women aged 40–80 years | 200 mg | 10 weeks | 35 |
| [Study of the antioxidant drug "Karinat" in patients with chronic atrophic gastritis] 2004 · Karinat · Patients with chronic multifocal atrophic gastritis | 10 mg | 26 weeks | 34 |
| [Study of an antioxidant dietary supplement "Karinat" in patients with benign breast disease] 2004 · Karinat · Patients with benign breast disease, including mastopathy | 10 mg | 26 weeks | 33 |
| Effect of a mixture of micronutrients, but not of bovine colostrum concentrate, on immune function parameters in healthy volunteers: a randomized placebo-controlled study 2006 · Micronutrients · Healthy, non-smoking men and women aged 40–80 years | 200 mg | 10 weeks | 31 |
| Increased vitamin plasma levels in Swedish military personnel treated with nutrients prior to automatic weapon training 2011 · Nutrients (active treatment) · Normally hearing Swedish military personnel, officers and military academy trainees, ages 18 and older, undergoing weapons training | 305 mg | 2 days | 31 |
| A Dermonutrient Containing Special Collagen Peptides Improves Skin Structure and Function: A Randomized, Placebo-Controlled, Triple-Blind Trial Using Confocal Laser Scanning Microscopy on the Cosmetic Effects and Tolerance of a Drinkable Collagen Supplement 2020 · test product (Elasten) · Women aged 40–70 years; healthy, without a stated skin disease | 2.3 mg | 12 weeks | 30 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 15 mg | 2 years | 30 |
| The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis 2021 · OMEGA group · Adults with relapsing-remitting multiple sclerosis; mean age 38.4 years (SD 7.1) | 782 mg | 2 years | 27 |
| EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors 2003 · PUFA supplement group · Children with ADHD-like symptoms who also reported thirst and skin problems; age and sex not stated | 24 mg | 120 days | 25 |
| Effect of γ-tocopherol supplementation on premenstrual symptoms and natriuresis: a randomized, double-blind, placebo-controlled study 2023 · γ-Toc intake · Healthy Japanese women aged 20–40 with cyclical water-retention symptoms during the luteal phase | 386 mg | 7 days | 25 |
| Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma 2018 · γT treatment · Adults aged 18–50 with mild intermittent or mild persistent asthma | 1.31 g | 2 weeks | 23 |
| The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment 2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment | 782 mg | 26 weeks | 23 |
| Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins 1999 · Methionine load with antioxidant vitamins · Healthy adults aged 25 to 45 years; 10 men and 10 women | 800 IU | 1 day | 20 |
| Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported. | 782 mg | 913 days | 20 |
| Consumption of Nutritionally Enriched Hen Eggs Enhances Endothelium-Dependent Vasodilation via Cyclooxygenase Metabolites in Healthy Young People-A Randomized Study 2023 · Nutri4 (enriched eggs) · Healthy young adults aged 18–30 years, both sexes, with normal blood pressure and BMI | 3.29 mg | 3 weeks | 20 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 30 mg | 1 year | 15 |
| Effects of Supplementation with Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins, Combined with High-Intensity Functional Training, on Exercise Performance and Body Composition: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · experimental supplement group (SG) · Healthy young adult women and men, aged approximately 29 years, familiar with high-intensity functional training and with at least 6 months of similar exercise experience | 782 mg | 8 weeks | 10 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 30 IU | 2 weeks | — |
| French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial 2011 · antioxidant supplementation · French adults aged 45–60 years enrolled in the SU.VI.MAX study | 30 mg | 2922 days | — |
| The impact of vitamins and/or mineral supplementation on blood pressure in type 2 diabetes 2004 · group MV · People with type 2 diabetes; age and sex not reported | 150 mg | 90 days | 17 |
| Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes 2002 · alpha-tocopherol group · Korean patients with type 2 diabetes treated with continuous subcutaneous insulin infusion | 200 mg | 60 days | 48 |
| Polymorphisms at cytokine genes may determine the effect of vitamin E on cytokine production in the elderly 2009 · vitamin E · elderly men and women, mean age 83 years | 182 mg | 1 year | 47 |
| [Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus] 2010 · vitamin E group · Patients with newly diagnosed type 2 diabetes mellitus; age and sex not reported | 200 mg | 548 days | 36 |
| Effect of vitamins on the lipid profile of patients on regular hemodialysis 2000 · vitamin E · hemodialysis patients; age and sex not reported | 200 mg | 90 days | 21 |
| Response of hypercholesterolemic subjects to administration of tocotrienols 1995 · gamma-tocotrienol group · Hypercholesterolemic subjects; age and sex not specified | 200 mg | 4 weeks | 16 |
| Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee) 1991 · palmvitee · Hypercholesterolemic human subjects with serum cholesterol 6.21–8.02 mmol/L | 200 mg | 8 weeks | 15 |
| Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans 2000 · alpha-tocotrienyl acetate · People with hypercholesterolemia; age and sex not reported | 250 mg | 8 weeks | 13 |
| Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans 2000 · delta-tocotrienyl acetate · People with hypercholesterolemia; age and sex not reported | 250 mg | 8 weeks | 13 |
| Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans 2000 · gamma-tocotrienyl acetate · People with hypercholesterolemia; age and sex not reported | 250 mg | 8 weeks | 12 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · CHD patients, 200 mg/day · 12 patients with coronary heart disease | 200 mg | 3 weeks | 12 |
| Vitamin E and vitamin C supplementation in patients with chronic obstructive pulmonary disease 2007 · 200 mg/day vitamin E (E200) · Patients with stable COPD | 200 mg | 12 weeks | 9 |
| Vitamin E supplementation inhibits muscle damage and inflammation after moderate exercise in hypoxia 2016 · hypoxia after vitamin E supplementation · Nine volunteers; age and sex not reported; no diagnosed condition stated | 250 mg | 1 day | 9 |
| Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee) 1991 · gamma-tocotrienol · Hypercholesterolemic subjects with serum cholesterol greater than 7.84 mmol/L | 200 mg | 4 weeks | 7 |
| Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2'-deoxyuridine (HMdU) 1999 · 200 mg/day alpha-tocopherol group · Eligible subjects in a phase II chemoprevention trial; age, sex, and condition are not specified | 200 mg | 4 weeks | — |
| Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2'-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men 2000 · vitamin E · men described as nondepleted; age and condition not stated | 182 mg | 3 years | — |
| Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men 2001 · vitamin E group · Clinically healthy men with mild hypercholesterolemia and normal vitamin C and E levels | 200 mg | 1 year | — |
| Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects 2006 · 268 mg/day AT · healthy adults; sex and age range not specified | 268 mg | 4 weeks | — |
| Effect of vitamin E on reperfusion injuries during reconstructive vascular operations on lower limbs 2010 · E-vitamin group · Patients with angiography-proven atherosclerotic femoral superficial (AFS) occlusion undergoing supragenual reconstruction; age and sex not stated | 200 mg | 8 days | — |
| Vitamin E supplementation protects erythrocyte membranes from oxidative stress in healthy Chinese middle-aged and elderly people 2012 · VE2 · Healthy adults aged 55–70 years | 200 mg | 120 days | — |
| Effects of delta-tocotrienol supplementation on Glycemic Control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial 2021 · tocotrienol group · Adults with type 2 diabetes mellitus taking oral hypoglycemic agents; age and sex not reported | 250 mg | 24 weeks | — |
| A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins 1998 · RRR-alpha-tocopheryl acetate supplementation · Smoking men; age not reported | 200 mg | 60 days | — |
| Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients 2013 · TRF group · Adults aged 18 years or older receiving chronic hemodialysis for end-stage renal disease | 220 mg | 16 weeks | 41 |
| Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly 2010 · Tx1 · Older adults aged approximately 68 years, men and women, healthy or with controlled chronic disease | 400 IU | 1 year | 30 |
| Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly 2010 · Tx2 · Older adults aged approximately 69 years, men and women, healthy or with controlled chronic disease | 400 IU | 1 year | 30 |
| Cardiovascular effects of oral Supplementation of vitamin C, E and folic acid in young healthy males 2004 · vitamin intervention · 31 young healthy male adults; 14 received the vitamin intervention | 800 mg | 12 weeks | 14 |
| Effect of antioxidants combined to resistance training on BMD in elderly women: a pilot study 2009 · antioxidants · Postmenopausal women, mean age 66.1 years, described as healthy | 600 mg | 26 weeks | 8 |
| Effect of antioxidants combined to resistance training on BMD in elderly women: a pilot study 2009 · exercise and antioxidants · Postmenopausal women, mean age 66.1 years, described as healthy | 600 mg | 26 weeks | 8 |
| Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension 2008 · vitamins C+E · Men aged 35–60 with grade 1 essential hypertension, without obesity, dyslipidaemia or diabetes | 400 IU | 8 weeks | — |
| Alpha-tocopherol supplementation for men with existing coronary artery disease: a feasibility study 1999 · alpha-tocopherol group · male veterans with existing coronary artery disease | 400 mg | 26 weeks | 27 |
| Effect of Omega-3 and Vitamins E + C Supplements on the Concentration of Serum B-Vitamins and Plasma Redox Aminothiol Antioxidant Status in Elderly Men after Strength Training for Three Months 2016 · group III · Healthy men, mean age 60 ± 6 years, undertaking strength training | 235 mg | 90 days | 16 |
| Effects of gamma-tocopherol supplementation on thrombotic risk factors 2007 · 100 mg/day gamma-T group · Healthy subjects; age and sex not reported | 100 mg | 5 weeks | 14 |
| Effects of soy protein on levels of remnant-like particles cholesterol and vitamin E in healthy men 2001 · SPI with vitamin E · healthy men; age not reported | 200 mg | 3 weeks | 12 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · CHD patients, 100 mg/day · 12 patients with coronary heart disease | 100 mg | 3 weeks | 12 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · CHD patients, 400 mg/day · 12 patients with coronary heart disease | 400 mg | 3 weeks | 12 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · Healthy subjects, 400 mg/day · 12 healthy subjects | 400 mg | 3 weeks | 12 |
| A randomized, crossover study to evaluate α-tocopherol bioavailability via a microemulsion gel or dry tablet delivery in healthy adults 2024 · microemulsion gel formula · Healthy adults; mean age 37.3 years | 288 mg | 1 day | 12 |
| A randomized, crossover study to evaluate α-tocopherol bioavailability via a microemulsion gel or dry tablet delivery in healthy adults 2024 · dry solid tablet · Healthy adults; mean age 37.3 years | 288 mg | 1 day | 12 |
| Pharmacokinetics and bioavailability of the RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration 1993 · RRR alpha-tocopherol · men; age and health condition not reported | 400 mg | 1 day | 12 |
| Pharmacokinetics and bioavailability of the RRR and all racemic stereoisomers of alpha-tocopherol in humans after single oral administration 1993 · all rac alpha-tocopherol · men; age and health condition not reported | 400 mg | 1 day | 12 |
| Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations 1996 · B: all-rac-alpha-tocopheryl acetate, fat-soluble preparation · Patients aged 0.7–29.8 years with cystic fibrosis | 400 mg | 6 weeks | 10 |
| Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations 1996 · C: all-rac-alpha-tocopheryl acetate, water-miscible preparation · Patients aged 0.7–29.8 years with cystic fibrosis | 400 mg | 6 weeks | 9 |
| The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix 2004 · toast with butter (17.5 g fat) · Eight healthy individuals; age and sex not stated | 150 mg | 1 day | 8 |
| The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix 2004 · cereal with full-fat milk (17.5 g fat) · Eight healthy individuals; age and sex not stated | 150 mg | 1 day | 8 |
| The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix 2004 · cereal with semi-skimmed milk (2.7 g fat) · Eight healthy individuals; age and sex not stated | 150 mg | 1 day | 8 |
| The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix 2004 · water (0 g fat) · Eight healthy individuals; age and sex not stated | 150 mg | 1 day | 8 |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · olive oil (OO) · Healthy subjects; age and sex not specified | 205 mg | 12 weeks | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · safflower oil (SO) · Healthy subjects; age and sex not specified | 205 mg | 12 weeks | — |
| Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products 2001 · group A · Healthy Italian adults; age and sex not specified | 300 mg | 15 days | — |
| Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products 2001 · group B · Healthy Italian adults; age and sex not specified | 300 mg | 15 days | — |
| A European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses 2002 · Alpha-tocopherol · Healthy men and women aged 25–45 years from five European regions | 100 mg | — | — |
| Vitamin C pharmacokinetics of plain and slow release formulations in smokers 2004 · Plain-release group · Healthy men aged 20–65 years who smoked at least 5 cigarettes per day | 182 mg | 4 weeks | — |
| Vitamin C pharmacokinetics of plain and slow release formulations in smokers 2004 · Slow-release group · Healthy men aged 20–65 years who smoked at least 5 cigarettes per day | 182 mg | 4 weeks | — |
| Oral supplementation with all-Rac- and RRR-alpha-tocopherol increases vitamin E levels in human sebum after a latency period of 14-21 days 2004 · RRR-alpha-toc group · Volunteers; age and sex not stated, with no condition reported | 400 mg | 2 weeks | — |
| Oral supplementation with all-Rac- and RRR-alpha-tocopherol increases vitamin E levels in human sebum after a latency period of 14-21 days 2004 · all-rac-alpha-toc group · Volunteers; age and sex not stated, with no condition reported | 400 mg | 2 weeks | — |
| Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E 2006 · TRE 160 mg · Healthy males; age not specified | 160 mg | 60 days | — |
| Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E 2006 · TRE 320 mg · Healthy males; age not specified | 320 mg | 60 days | — |
| Plasma vitamin C and tocotrienols changes in response to dietary supplementation among young male adults 2010 · Combination · young male police recruits | 200 mg | 8 weeks | — |
| Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers 2011 · TRF study group · Healthy female volunteers | 400 mg | 60 days | — |
| Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients 2012 · TE supplementation · Adults, including healthy participants and surgical patients; prospective liver-transplantation patients were included | 400 mg | 20 weeks | — |
| Supplementation with tocotrienol-rich fraction alters the plasma levels of Apolipoprotein A-I precursor, Apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals 2013 · TRF · Young adults aged 32 ± 2 years and older adults aged 52 ± 2 years; no condition stated | 150 mg | 26 weeks | — |
| The influence of antioxidant nutrients on platelet function in healthy volunteers 1997 · vitamin E · Healthy volunteers aged 20–50 years | 300 mg | 8 weeks | — |
| Effects of a Novel Nutraceutical Combination (Aquilea Colesterol(®)) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial 2019 · nutraceutical combination group · Men and women aged 35–75 with primary hypercholesterolemia and low-to-moderate cardiovascular risk | 12 mg | 90 days | 20 |
| Combination oral antioxidant supplementation reduces blood pressure 1997 · antioxidants · Hypertensive and normotensive adult outpatients; 21 were attending for hypertension treatment and 17 were normotensive outpatients with minor gastrointestinal complaints. | 600 mg | 8 weeks | — |
| Positive Association of Vitamin E Supplementation with Hemoglobin Levels in Mildly Anemic Healthy Pakistani Adults 2015 · intervention group · Mildly anemic healthy adults in Karachi, Pakistan; ages and sex distribution not stated | 400 mg | 90 days | 82 |
| Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study 2025 · vitamin E 300 mg group · Adults aged 18–75 with biopsy-proven MASH, without diabetes | 300 mg | 96 weeks | 58 |
| Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study 2025 · vitamin E 300 mg group · Adults aged 18–75 with biopsy-proven MASH, without diabetes | 300 mg | 96 weeks | 58 |
| Platelet function in stroke/transient ischemic attack patients treated with tocotrienol 2020 · 400mg TCT · Adults with atherothrombotic, cardio-embolic or cryptogenic TIA or stroke within 6 months, with post-stroke mRS <4 and no indication for anticoagulation | 400 mg | 1 year | 51 |
| Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial 2022 · α-tocopherol · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 536 mg | 48 weeks | 50 |
| Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression 2022 · αTF group · Men and women aged 20–70 years with non-alcoholic fatty liver disease | 536 mg | 48 weeks | 50 |
| Effects of delta-tocotrienol supplementation on glycaemic control in individuals with prediabetes: A randomized controlled study 2022 · Group A · Adults aged 18–60 years with prediabetes | 300 mg | 12 weeks | 40 |
| Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations 2016 · anti-oxidant intervention group · Adults aged 20–79 with mild-to-moderate chronic kidney disease (stages 3–4), receiving background ACE-inhibitor or ARB treatment | 300 mg | 26 weeks | 34 |
| [Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases] 2012 · Experimental cases with oligospermia · Infertile men with oligospermia | 300 mg | 90 days | 33 |
| Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial 2012 · Chlorella group · People with non-alcoholic fatty liver disease; age and sex not specified | 200 mg | 90 days | 33 |
| Effects of meat-based, meat-based with α-tocopherol, and pesco-vegetarian diets on biomarkers associated with colorectal cancer risk: a randomized behavioral intervention trial 2025 · MBD-T · Clinically healthy adults aged 18–50 years | 100 mg | 12 weeks | 33 |
| Effect of palm-based tocotrienols and tocopherol mixture supplementation on platelet aggregation in subjects with metabolic syndrome: a randomised controlled trial 2017 · PTT mixture intervention · Adults aged 25–60 with metabolic syndrome | 400 mg | 2 weeks | 31 |
| A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease 2021 · intervention group · Adults aged 18–75 with type 2 diabetes and diabetic kidney disease, including reduced eGFR or microalbuminuria | 400 mg | 1 year | 31 |
| Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: A prospective, randomized trial 2015 · Group A · Men with idiopathic oligoasthenozoospermia | 400 mg | 26 weeks | 30 |
| Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: A prospective, randomized trial 2015 · Group C · Men with idiopathic oligoasthenozoospermia | 400 mg | 26 weeks | 30 |
| Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial 2025 · Vitamin E supplementation with desferrioxamine (DFO) · Children with transfusion-dependent β-thalassemia receiving DFO | 400 mg | 1 year | 30 |
| Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial 2025 · Vitamin E supplementation with deferiprone (DFP) · Children with transfusion-dependent β-thalassemia receiving DFP | 400 mg | 1 year | 30 |
| Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial 2025 · Vitamin E supplementation with deferasirox (DFX) · Children with transfusion-dependent β-thalassemia receiving DFX | 400 mg | 1 year | 30 |
| Activated and Micronized Zeolite in the Modulation of Cellular Oxidative Stress in Mexican Smokers: A Randomized Clinical Trial 2017 · vitamin E · Mexican smokers without lung diseases | 400 mg | 30 days | 29 |
| Comparing the effects of vitamin E tocotrienol-rich fraction supplementation and α-tocopherol supplementation on gene expression in healthy older adults 2019 · Tocotrienol-Rich Fraction (TRF) · Healthy adults aged 50–55 years, male and female, without significant clinical disease | 150 mg | 26 weeks | 24 |
| Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis 2006 · HD treatment group · Adults with end-stage kidney disease receiving hemodialysis; age and sex not specified | 300 mg | 20 weeks | 19 |
| Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans 2002 · 100 mg/day TRF25 group · Hypercholesterolemic human subjects on the AHA Step-1 diet; age and sex not specified | 100 mg | 5 weeks | 18 |
| Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis 2006 · PD treatment group · Adults with end-stage kidney disease receiving peritoneal dialysis; age and sex not specified | 300 mg | 20 weeks | 13 |
| Effect of vitamin E therapy on sexual functions of uremic patients in hemodialysis 1992 · vitamin E · uremic patients on hemodialysis | 300 mg | 8 weeks | 12 |
| Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study 2021 · Vitamin E · Healthy adult volunteers; age and sex range not specified | 100 mg | 4 weeks | 12 |
| Supplementation with vitamins C and E enhances cytokine production by peripheral blood mononuclear cells in healthy adults 1996 · vitamin E group · healthy adults; age range and sex not reported | 400 mg | 4 weeks | 10 |
| Vitamin E and vitamin C supplementation in patients with chronic obstructive pulmonary disease 2007 · 400 mg/day vitamin E (E400) · Patients with stable COPD | 400 mg | 12 weeks | 9 |
| Antioxidant effect on urinary excretion of malondialdehyde in non-athletes during aerobic training 2009 · Vitamin E supplemented group · Previously sedentary non-athletes participating in moderate-intensity aerobic training; age and sex not reported | 133 mg | 8 weeks | 7 |
| Vitamin E supplement improves erythrocyte membrane fluidity of thalassemia: an ESR spin labeling study 2012 · vitamin E supplementation group · splenectomized patients with beta-thalassemia/hemoglobin E; age and sex not reported | 350 mg | 30 days | 5 |
| Oral vitamins C and E as additional treatment in patients with acute anterior uveitis: a randomised double masked study in 145 patients 1999 · vitamin group · Patients with acute anterior uveitis; age and sex not specified | 200 mg | 8 weeks | — |
| Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2'-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men 2000 · vitamin C and vitamin E combination · men described as nondepleted; age and condition not stated | 182 mg | 3 years | — |
| Long-term pharmacologic doses of vitamin E only moderately affect the erythrocytes of patients with type 1 diabetes mellitus 2001 · Group S · Patients with type 1 diabetes mellitus; age and sex not reported | 504 mg | 1 year | — |
| Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men 2001 · both vitamins group (CellaVie) · Clinically healthy men with mild hypercholesterolemia and normal vitamin C and E levels | 200 mg | 1 year | — |
| Serum ex vivo lipoprotein oxidizability in patients with ischemic heart disease supplemented with vitamin E 2002 · vitamin E supplemented group · 32 patients with ischemic heart disease and moderate hypercholesterolemia: 16 men and 16 postmenopausal women | 400 mg | 6 weeks | — |
| Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults 2004 · Vitamin E for the first 3-month period · HIV-positive adults with fasting triglycerides ≥2 mmol/L on stable antiretroviral therapy | 500 mg | 90 days | — |
| Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults 2004 · Fenofibrate plus Vitamin E for the additional 3-month period · HIV-positive adults with fasting triglycerides ≥2 mmol/L on stable antiretroviral therapy | 500 mg | 90 days | — |
| Vitamin E improves fibrinolytic activity in patients with coronary spastic angina 2004 · vitamin E group · Patients with coronary spastic angina | 400 mg | 30 days | — |
| The aging/precancerous gastric mucosa: a pilot nutraceutical trial 2004 · vitamin E · Elderly patients with HP-negative atrophic gastritis and intestinal metaplasia | 300 mg | 26 weeks | — |
| Vitamin C supplementation decreases oxidative DNA damage in mononuclear blood cells of smokers 2004 · Slow-release vitamin C with plain-release vitamin E · Male smokers | 182 mg | 4 weeks | — |
| Vitamin C supplementation decreases oxidative DNA damage in mononuclear blood cells of smokers 2004 · Plain-release vitamin C with plain-release vitamin E · Male smokers | 182 mg | 4 weeks | — |
| Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes 2006 · 500 mg alpha-tocopherol/d · Subjects with type 2 diabetes; age and sex not specified | 500 mg | 6 weeks | — |
| Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes 2006 · 500 mg mixed tocopherols/d · Subjects with type 2 diabetes; age and sex not specified | 500 mg | 6 weeks | — |
| Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects 2006 · 134 mg/day AT · healthy adults; sex and age range not specified | 134 mg | 4 weeks | — |
| Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes 2007 · alpha-tocopherol (alphaT) · Patients with type 2 diabetes; age and sex not reported | 500 mg | 6 weeks | — |
| Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes 2007 · mixed tocopherols · Patients with type 2 diabetes; age and sex not reported | 500 mg | 6 weeks | — |
| Reduction of DNA damage in older healthy adults by Tri E Tocotrienol supplementation 2008 · Tri E Tocotrienol · Healthy adults aged 37–78 years | 160 mg | 26 weeks | — |
| [Study the effect of antioxidant vitamin E, vitamin C and beta-carotene supplement on erythrocyte functions in elderly person] 2008 · Group 4 · Adults aged 60–75 years; elderly participants | 200 mg | 16 weeks | — |
| Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis 2008 · group E (vitamin E) · Adults aged 19–69 with active rheumatoid arthritis | 400 mg | 12 weeks | — |
| Vitamin E supplementation modulates gingival crevicular fluid lipid peroxidation and antioxidant levels in patients with orthodontic tooth movement 2012 · Vitamin E · Patients aged 13–18 years receiving non-extraction orthodontic treatment | 300 mg | 30 days | — |
| Vitamin E supplementation protects erythrocyte membranes from oxidative stress in healthy Chinese middle-aged and elderly people 2012 · VE1 · Healthy adults aged 55–70 years | 100 mg | 120 days | — |
| Vitamin E supplementation protects erythrocyte membranes from oxidative stress in healthy Chinese middle-aged and elderly people 2012 · VE3 · Healthy adults aged 55–70 years | 300 mg | 120 days | — |
| Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter 2014 · mixed tocotrienols group · Volunteers aged 35 years or older with cardiovascular risk factors and MRI-confirmed white matter lesions | 400 mg | 2 years | — |
| Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial 2018 · low TT · Postmenopausal women with osteopenia | 430 mg | 12 weeks | — |
| Vitamin E decreases urine lipid peroxidation products in young healthy human volunteers under normal conditions 1996 · 100 mg of vitamin E · 21 young healthy men | 100 mg | 30 days | — |
| Oxy free radical system in heart failure and therapeutic role of oral vitamin E 1996 · vitamin E supplementation · Adults with heart failure; the abstract says 12 patients were studied prospectively, but separately reports a group of 13 patients with ejection fraction 40%. | 400 mg | 4 weeks | — |
| Effect of 3 months vitamin E supplementation on indices of the cellular and humoral immune response in elderly subjects 1997 · vitamin E group · Adults aged 65 years and over | 100 mg | 90 days | — |
| Erythrocyte membrane fatty acid composition of smokers and non-smokers: effects of vitamin E supplementation 1998 · smokers receiving vitamin E · adult male smokers | 280 mg | 10 weeks | — |
| Erythrocyte membrane fatty acid composition of smokers and non-smokers: effects of vitamin E supplementation 1998 · non-smokers receiving vitamin E · adult male non-smokers | 280 mg | 10 weeks | — |
| Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men 2012 · α-tocopherol supplementation · Middle-aged male smokers | 50 mg | 3 years | 2,112 |
| Effect of maternal supplementation with vitamin E on the concentration of α-tocopherol in colostrum 2017 · supplemented group · healthy adult pregnant women who were lactating when colostrum was collected | 400 IU | 1 day | 60 |
| Interactions between vitamins C and E in human subjects 2000 · Vitamin E supplementation · healthy adults; sex and age range not stated | 73.5 mg | 6 weeks | 30 |
| The effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial 2016 · vitamin E supplements · Patients with diabetic nephropathy; age and sex not stated | 1,200 IU | 12 weeks | 30 |
| Partial resistance of low density lipoprotein to oxidation in vivo after increased intake of berries 2000 · supplement group · Healthy 60-year-old men | 100 mg | 8 weeks | 20 |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALAPL group · Patients with diabetes; age and sex not reported | 200 mg | 90 days | 20 |
| α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial 2015 · nonfat milk · Healthy adults and adults with metabolic syndrome | 15 mg | 1 day | 20 |
| α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial 2015 · reduced-fat milk · Healthy adults and adults with metabolic syndrome | 15 mg | 1 day | 20 |
| α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial 2015 · whole milk · Healthy adults and adults with metabolic syndrome | 15 mg | 1 day | 20 |
| A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects 2015 · Naturale3 Gamma Delta Tocotrienol (GDT) · Healthy volunteers aged 22–27 years; 9 men and 3 women enrolled | 600 mg | 1 day | 12 |
| A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects 2015 · Tocovid Suprabio (Tocotrienol-rich fraction; TRF) · Healthy volunteers aged 22–27 years; 9 men and 3 women enrolled | 554 mg | 1 day | 12 |
| Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin 2004 · group AE · Patients with type 1 diabetes mellitus and high cholesterol; age and sex not reported | 750 IU | 26 weeks | 11 |
| Effect of an 8-weeks aerobic training program in elderly on oxidative stress and HSP72 expression in leukocytes during antioxidant supplementation 2012 · antioxidant supplemented sedentary group (AS) · Healthy septuagenarians, men and women, mean age 73.4 years; no stated disease or nutrient deficiency. | 100 mg | 8 weeks | 8 |
| Effect of an 8-weeks aerobic training program in elderly on oxidative stress and HSP72 expression in leukocytes during antioxidant supplementation 2012 · antioxidant supplemented and aerobically trained group (AT) · Healthy septuagenarians, men and women, mean age 75.8 years; no stated disease or nutrient deficiency. | 100 mg | 8 weeks | 8 |
| Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients 2005 · Control group · Patients with chronic hepatitis C receiving interferon alpha-2b and ribavirin; age and sex not reported | 300 mg | 24 weeks | 5 |
| Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans 2000 · vitamin E group · Volunteers; age, sex, and health status not specified | 50 mg | 2 weeks | — |
| Accumulation and interactions of beta-carotene and alpha-tocopherol in patients with adenomatous polyps 2002 · natural VE · Volunteers with colonic adenomatous polyps; age and sex not reported | 400 IU | 43 days | — |
| Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans 2003 · alpha-tocopherol · adult nonsmokers | 400 IU | 60 days | — |
| Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque 2004 · vitamin E supplementation · patients with severe atherosclerosis who were candidates for carotid endarterectomy | 900 mg | 6 weeks | — |
| Delivery of vitamin E to the skin by a novel liquid skin cleanser: comparison of topical versus oral supplementation 2004 · Dietary vitamin E supplementation group · Panelists; age, sex, and health status not stated | 400 IU | — | — |
| GLV supplements increased plasma beta-carotene, vitamin C, zinc and hemoglobin in young healthy adults 2006 · GLV with vitamin E · Young adults; sex, age range and health condition not reported | 100 mg | 3 weeks | — |
| Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients 2007 · Aqua-E · Patients with cystic fibrosis and documented malabsorption | 20 mL | 1 day | — |
| Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E 2006 · TRE 80 mg · Healthy males; age not specified | 80 mg | 60 days | — |
| Combination treatment with high-dose vitamin C and alpha-tocopherol does not enhance respiratory-tract lining fluid vitamin C levels in asthmatics 2009 · 500 mg tocopherol and 2 g vitamin C · Adults aged 18–50 with allergic moderate-to-severe persistent asthma | 500 mg | 12 weeks | — |
| Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome 2010 · 100 IU /day vitamin E group · Chinese women with metabolic syndrome | 100 IU | 120 days | — |
| Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome 2010 · 200 IU /day vitamin E group · Chinese women with metabolic syndrome | 200 IU | 120 days | — |
| Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome 2010 · 300 IU /day vitamin E group · Chinese women with metabolic syndrome | 300 IU | 120 days | — |
| α-Tocopherol in breast milk of women with preterm delivery after a single postpartum oral dose of vitamin E 2016 · supplemented group · Women who had given birth prematurely and were breastfeeding | 400 IU | 1 day | — |
| Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture 2021 · 1-week supplementation group · Men aged 42–77 with localized prostate cancer undergoing radical prostatectomy | 798 mg | 7 days | — |
| Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture 2021 · 2-week supplementation group · Men aged 42–77 with localized prostate cancer undergoing radical prostatectomy | 798 mg | 2 weeks | — |
| Excretion of alpha-tocopherol into human seminal plasma after oral administration 1995 · 600 mg/day group · Unselected male volunteers | 600 mg | 3 weeks | — |
| Excretion of alpha-tocopherol into human seminal plasma after oral administration 1995 · 800 mg/day group · Unselected male volunteers | 800 mg | 3 weeks | — |
| Excretion of alpha-tocopherol into human seminal plasma after oral administration 1995 · 1200 mg/day group · Unselected male volunteers | 1.2 g | 3 weeks | — |
| Depletion of plasma vitamin C but not of vitamin E in response to cardiac operations 1994 · vitamin E supplementation · Patients undergoing coronary bypass operations | 900 mg | 4 weeks | — |
| Effects of dietary supplementation of alpha-tocopherol on plasma glutathione and DNA repair activities 1996 · 15 mg/day alpha-tocopherol group · healthy volunteers; age and sex not stated | 15 mg | 4 weeks | — |
| Effects of dietary supplementation of alpha-tocopherol on plasma glutathione and DNA repair activities 1996 · 60 mg/day alpha-tocopherol group · healthy volunteers; age and sex not stated | 60 mg | 4 weeks | — |
| Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group 1998 · subjects receiving 2,000 IU vitamin E orally per day · Patients with early untreated Parkinson's disease | 2,000 IU | — | — |
| Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation 1998 · Group (1) · Healthy volunteers | 2 g | 50 days | — |
| An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients 2016 · Group A (Vitamin E) · Adults aged 18–80 with nonalcoholic fatty liver disease and elevated transaminases, without diabetes or cirrhosis | 800 IU | 52 weeks | 100 |
| Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial 2016 · α-tocopherol (vitamin E) intervention · Adults with type 1 diabetes, eligible by age and diabetes duration or cardiovascular disease history; Hp genotype groups 1-1, 2-1, and 2-2 | 400 IU | 8 weeks | 87 |
| Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis 2013 · vitamin E · Adults with histologically defined non-alcoholic steatohepatitis, without diabetes; ages 19–71 in the analysis cohort | 800 IU | 96 weeks | 84 |
| Serum Metabolomic Response to Low- and High-Dose Vitamin E Supplementation in Two Randomized Controlled Trials 2020 · alpha-tocopheryl acetate (ATA), VEAPS · men aged 40 and older without clinical evidence of diabetes or cardiovascular disease | 400 IU | 2 years | 73 |
| Neutrophil superoxide-anion generating capacity in chronic smoking: effect of long-term alpha-tocopherol therapy 2003 · alpha-tocopherol · adult male chronic smokers | 400 IU | 2 years | 64 |
| Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial 2011 · vitamin E · Children aged 8–17 years with nonalcoholic fatty liver disease and persistently elevated alanine aminotransferase; children with diabetes or cirrhosis were excluded | 800 IU | 96 weeks | 58 |
| Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin 2021 · vitamin E · Children aged 8–18 years with biopsy-proven NAFLD and persistently elevated ALT | 800 IU | 96 weeks | 58 |
| Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions 2003 · alpha-tocopherol · Carotid endarterectomy patients with established atherosclerotic lesions; age and sex not specified | 500 IU | — | 53 |
| Serum Metabolomic Response to Low- and High-Dose Vitamin E Supplementation in Two Randomized Controlled Trials 2020 · ATA alone, ATBC · male smokers aged 50–69 years | 50 IU | 2227 days | 50 |
| Platelet function in stroke/transient ischemic attack patients treated with tocotrienol 2020 · 800 mg TCT · Adults with atherothrombotic, cardio-embolic or cryptogenic TIA or stroke within 6 months, with post-stroke mRS <4 and no indication for anticoagulation | 800 mg | 1 year | 50 |
| Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial 2022 · δ-tocotrienol · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 600 mg | 48 weeks | 50 |
| Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression 2022 · δT3 group · Men and women aged 20–70 years with non-alcoholic fatty liver disease | 600 mg | 48 weeks | 50 |
| New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial 2025 · group 1 · Patients with nonalcoholic steatohepatitis (NASH); age and sex not stated | 800 IU | 26 weeks | 45 |
| Vitamin E Improves Serum Paraoxonase-1 Activity and Some Metabolic Factors in Patients with Type 2 Diabetes: No Effects on Nitrite/Nitrate Levels 2016 · vitamin E group · Patients with type 2 diabetes aged 30–60 years | 400 IU | 8 weeks | 42 |
| Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) 1997 · Vitamin E group · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus | 15 mg/kg | 1 year | 42 |
| Role of δ-tocotrienol and resveratrol supplementation in the regulation of micro RNAs in patients with metabolic syndrome: A randomized controlled trial 2023 · TRM group · Adults with metabolic syndrome; age range and sex not specified | 500 mg | 24 weeks | 41 |
| Vitamin E supplementation and plasma 8-isoprostane and adiponectin in overweight subjects 2007 · Vitamin E · Overweight/obese adults with BMI >27 kg/m²; 60 women and 20 men enrolled | 800 IU | 26 weeks | 39 |
| The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome 2013 · Vitamin E · People with metabolic syndrome | 100 IU | 1 year | 36 |
| Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study 2021 · PTVE group · Patients with histologically proven non-alcoholic steatohepatitis (NASH) | 800 IU | 1 year | 36 |
| Measures of cellular oxidative damage following vitamin E supplementation in young patients with transfusion-dependent thalassemia: a double-blind randomized controlled trial 2025 · Vitamin E · Patients aged 10–25 years with transfusion-dependent β- or α-thalassemia requiring at least 7 red blood cell transfusions per year; included splenectomized β-thalassemia, non-splenectomized β-thalassemia, and non-splenectomized α-thalassemia | 400 IU | 26 weeks | 36 |
| Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease 2018 · δ-tocotrienol group · Adults aged over 20 years of both sexes with ultrasound-proven fatty liver disease, fatty liver index ≥60, and persistent elevation of alanine transaminase | 600 mg | 12 weeks | 35 |
| Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial 2020 · δ-tocotrienol group · Patients with nonalcoholic fatty liver disease (age and sex not specified) | 600 mg | 24 weeks | 35 |
| Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study 2021 · VE group · Patients with histologically proven non-alcoholic steatohepatitis (NASH) | 800 IU | 1 year | 33 |
| Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study 2025 · vitamin E group · Adults with MASLD; age and sex not specified | 800 mg | 24 weeks | 32 |
| Effect of vitamin E on oxidative stress level in blood, synovial fluid, and synovial tissue in severe knee osteoarthritis: a randomized controlled study 2017 · Group B (vitamin E) · Adults aged 18 years or older with severe knee osteoarthritis scheduled for total knee arthroplasty | 400 IU | 60 days | 31 |
| [Synergistic antioxidative effect of vitamins E and C on low density lipoproteins from smokers and non-smokers subjects] 2004 · vitamins E and C combination · 20 healthy adult smokers and 10 healthy adult non-smokers | 400 mg | 30 days | 30 |
| Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity 2015 · VitE arm · Adults with NASH without diabetes | 800 IU | 96 weeks | 30 |
| The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · Magnesium plus vitamin E · Women aged 18–40 years with polycystic ovary syndrome | 400 mg | 12 weeks | 30 |
| Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease 1995 · vitamin E supplementation · Elderly patients (mean age 73.8 years), nondiabetic, moderately obese, with stable effort angina | 900 mg | 120 days | 30 |
| Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men 2003 · Vitamin E and selenium · Infertile men | 400 mg | 90 days | 28 |
| Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men 2001 · G5: atorvastatin 10 mg/day + vitamin E 600 IU/day · Men aged 55–64 with persistently elevated C3 levels and total cholesterol of 5.56 mmol/l | 600 IU | 90 days | 25 |
| The effects of vitamin E on platelet activity in beta-thalassaemia patients 2003 · Vitamin E supplementation · Adults with beta-thalassaemia/haemoglobin E; nine were splenectomized and 16 were non-splenectomized, and all had low plasma alpha-tocopherol levels | 525 IU | 90 days | 25 |
| The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial 2011 · 800 mg α-tocopherol · Patients with type 2 diabetes mellitus; age and sex not reported | 800 mg | 120 days | 25 |
| Sesame oil and vitamin E co-administration may improve cardiometabolic risk factors in patients with metabolic syndrome: a randomized clinical trial 2019 · Group A · Adults aged 30–70 years with metabolic syndrome | 400 mg | 8 weeks | 25 |
| The effect of vitamin E supplementation on biomarkers of endothelial function and inflammation among hemodialysis patients: A double-blinded randomized clinical trial 2020 · intervention group · Hemodialysis patients aged 20–60 years | 600 IU | 10 weeks | 25 |
| Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial 2020 · Vit E · Hemodialysis patients; age and sex ranges not reported | 400 IU | 8 weeks | 25 |
| Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients 1993 · vitamin E · elderly patients with type II diabetes | 900 mg | 90 days | 25 |
| Effect of vitamin E supplementation on circulating cell adhesion molecules pre- and post-coronary angioplasty 2000 · vitamin E group · Patients undergoing routine percutaneous transluminal coronary angioplasty; age and sex not reported | 800 IU | 30 days | 23 |
| The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial 2019 · ALA · Obese patients with non-alcoholic fatty liver disease; age and sex not specified | 400 mg | 12 weeks | 23 |
| Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study 1997 · Vitamin E treatment phase · Adults with hepatitis C refractory to alpha-interferon therapy; age and sex not reported | 800 IU | 12 weeks | 23 |
| Effects of postmenopausal hormone replacement and alpha-tocopherol on the lipid profiles and antioxidant status 1997 · third group (n = 22) · Postmenopausal women | 600 mg | 26 weeks | 22 |
| Increased antioxidant capacity in healthy volunteers taking a mixture of oral antioxidants versus vitamin C or E supplementation 2007 · vitamin E · Healthy adults aged 19–23 years | 400 IU | 7 days | 21 |
| Vitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation 1999 · vitamin E group · Hyperlipidaemic patients; age and sex not reported | 100 IU | — | 20 |
| Prolonged, low dose alpha-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation 2002 · alpha-tocopherol E · Healthy male volunteers, mean age 41.6 years | 50 IU | 20 weeks | 20 |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALA group · Patients with diabetes; age and sex not reported | 200 mg | 90 days | 20 |
| Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis 2011 · Group 2 · Adults aged 18–60 with end-stage renal disease receiving hemodialysis | 400 IU | 3 weeks | 20 |
| [Diabetes mellitus--a free radical-associated disease. Results of adjuvant antioxidant supplementation] 1993 · D-alpha-tocopherol group · Patients with diabetes mellitus and long-term diabetic late syndrome; age and sex not reported | 1,200 IU | 90 days | 20 |
| Effects of vitamin E on chronic hepatitis C genotype 3: a randomized, double-blind, placebo-controlled study 2014 · vitamin E group · Patients with HCV genotype 3 infection who were unable to receive or tolerate standard therapy, or did not respond to it; age and sex not reported. | 800 IU | 12 weeks | 19 |
| Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial 2016 · Control group · Adults aged 20–50 years with obesity (BMI 30–40 kg/m²) and non-alcoholic fatty liver disease, taking vitamin E as routine treatment | 400 IU | 8 weeks | 19 |
| The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes 2004 · group V · Adults with type 2 diabetes; age and sex not reported | 150 mg | 90 days | 18 |
| Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype 2008 · vitamin E · Adults with type 2 diabetes, Hp 2-2 genotype, and no antioxidant therapy at baseline | 400 IU | 60 days | 18 |
| Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults 2002 · RRR-alpha-tocopherol · Healthy adults | 400 IU | 2 weeks | 17 |
| Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial 2001 · vitamin E group · Patients with chronic hepatitis B; age and sex not specified | 600 mg | 90 days | 15 |
| Effect of tocopherol on platelet aggregation in non-insulin-dependent diabetes mellitus: ex vivo and in vitro studies 1992 · tocopherol · People with non-insulin-dependent diabetes mellitus; age and sex not stated | 600 mg | 6 weeks | 15 |
| Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis 2006 · UDCA/Vit E · Patients with biopsy-proven nonalcoholic steatohepatitis and elevated aminotransferase levels, drinking less than 40 g alcohol per week | 800 IU | 2 years | 15 |
| Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial 2024 · TRF treatment group · Children aged 10–18 years who were overweight or obese and had NAFLD | 50 mg | 26 weeks | 15 |
| Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial 2024 · TRF treatment group · Children aged 10–18 years who were overweight or obese and had NAFLD | 50 mg | 26 weeks | 15 |
| Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients 1993 · Vitamin E-supplemented non-insulin-dependent diabetic patients · Non-insulin-dependent diabetic patients | 900 mg | 120 days | 15 |
| Vitamin E improves arterial compliance in middle-aged men and women 1999 · vitamin E group · middle-aged men and women; no condition stated | 400 IU | 8 weeks | 14 |
| Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin 2006 · vitamin group · Patients with chronic hepatitis C receiving interferon-alpha-2b and ribavirin combination therapy; age and sex not reported | 500 mg | 8 weeks | 14 |
| Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics 2005 · alpha-tocopherol group · Women aged 40–70 with type 2 diabetes | 800 IU | 6 weeks | 13 |
| Vitamin E supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children 2000 · Vitamin E · Children with type 1 diabetes; ages and sex not stated | 100 IU | 90 days | 12 |
| Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein 1992 · alpha-tocopherol group · male subjects; no age range or condition stated | 800 IU | 12 weeks | 12 |
| Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin 2007 · control group · Patients with chronic hepatitis C receiving pegylated interferon alpha-2b and ribavirin therapy | 300 mg | 48 weeks | 12 |
| Relationship of blood thromboxane-B2 (TxB2) with lipid peroxides and effect of vitamin E and placebo supplementation on TxB2 and lipid peroxide levels in type 1 diabetic patients 1998 · vitamin E · adults with type 1 diabetes | 100 IU | 90 days | 12 |
| Antioxidant supplementation prevents exercise-induced lipid peroxidation, but not inflammation, in ultramarathon runners 2004 · antioxidants (AO) · Ultramarathon runners participating in a 50 km race; age and sex distribution not reported | 300 mg | 6 weeks | 11 |
| A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis 2004 · vitamin E alone · Nondiabetic, noncirrhotic patients with nonalcoholic steatohepatitis (NASH) | 400 IU | — | 10 |
| A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis 2004 · vitamin E and pioglitazone combination therapy · Nondiabetic, noncirrhotic patients with nonalcoholic steatohepatitis (NASH) | 400 IU | — | 10 |
| Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus 2007 · vitamin E group · Caucasian young adults with childhood-onset type 1 diabetes mellitus and persistent microalbuminuria; mean age 18.87 years; 7 male and 3 female overall | 1.2 g | 26 weeks | 10 |
| Pro-oxidant effect of alpha-tocopherol in patients with type 2 diabetes after an oral glucose tolerance test--a randomised controlled trial 2007 · α-tocopherol group · Caucasian men aged 50–65 with type 2 diabetes | 1,200 IU | 4 weeks | 10 |
| Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? 1991 · 1200 mg vitamin E group · Insulin-requiring diabetic patients; age and sex not stated | 1.2 g | 60 days | 10 |
| Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? 1991 · 600 mg vitamin E group · Insulin-requiring diabetic patients; age and sex not stated | 600 mg | 60 days | 10 |
| Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients 1993 · Vitamin E-supplemented healthy control subjects · Healthy control subjects | 900 mg | 120 days | 10 |
| Supplementation with vitamins C and E enhances cytokine production by peripheral blood mononuclear cells in healthy adults 1996 · vitamins C and E group · healthy adults; age range and sex not reported | 400 mg | 4 weeks | 10 |
| An evaluation of antiretroviral therapy associated with alpha-tocopherol supplementation in HIV-infected patients 2002 · alpha-tocopherol-supplemented group · HIV-seropositive patients | 800 mg | 60 days | 9 |
| The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study 1995 · 60 IU/d alpha-tocopherol group · Human subjects; age, sex, and health status not reported | 60 IU | 8 weeks | 8 |
| The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study 1995 · 200 IU/d alpha-tocopherol group · Human subjects; age, sex, and health status not reported | 200 IU | 8 weeks | 8 |
| The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study 1995 · 400 IU/d alpha-tocopherol group · Human subjects; age, sex, and health status not reported | 400 IU | 8 weeks | 8 |
| The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study 1995 · 800 IU/d alpha-tocopherol group · Human subjects; age, sex, and health status not reported | 800 IU | 8 weeks | 8 |
| The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study 1995 · 1200 IU/d alpha-tocopherol group · Human subjects; age, sex, and health status not reported | 1,200 IU | 8 weeks | 8 |
| Total radical-trapping antioxidant potential (TRAP) of plasma: effects of supplementation of young healthy volunteers with large doses of alpha-tocopherol and ascorbic acid 1993 · Group 3, alpha-tocopherol · Young healthy adults; age range and sex not reported | 1 g | 4 weeks | 8 |
| Increased serum and low-density-lipoprotein antioxidant potential after antioxidant supplementation in endurance athletes 1997 · antioxidant trial · Eight endurance athletes | 294 mg | 4 weeks | 8 |
| Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E 1991 · TPGS treatment · Six paediatric liver-transplant recipients and one young adult with severe hepatobiliary graft-versus-host disease after bone-marrow transplantation | 25 mg/kg | 60 days | 7 |
| Vitamin E supplementation and hepatic drug metabolism in humans 2009 · RRR-alpha-TOH group · 12 healthy subjects, with 6 assigned to this arm; age and sex not stated | 750 IU | 3 weeks | 6 |
| Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation 1999 · alpha-tocopherol with lovastatin · Men with verified coronary heart disease and hypercholesterolemia | 450 IU | 6 weeks | — |
| Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation 1999 · alpha-tocopherol with dummy tablets · Men with verified coronary heart disease and hypercholesterolemia | 450 IU | 6 weeks | — |
| Effects of vitamin E and glutathione on glucose metabolism: role of magnesium 1999 · vitamin E · Hypertensive patients; age and sex not specified | 600 mg | 4 weeks | — |
| Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes 1999 · Vitamin E · Adults with type 1 diabetes and age- and sex-matched control subjects | 400 IU | 8 weeks | — |
| Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2'-deoxyuridine (HMdU) 1999 · 15 mg/day alpha-tocopherol group · Eligible subjects in a phase II chemoprevention trial; age, sex, and condition are not specified | 15 mg | 4 weeks | — |
| Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2'-deoxyuridine (HMdU) 1999 · 60 mg/day alpha-tocopherol group · Eligible subjects in a phase II chemoprevention trial; age, sex, and condition are not specified | 60 mg | 4 weeks | — |
| The effect of vitamin E and vitamin C supplementation on LDL oxidizability and neutrophil respiratory burst in young smokers 2000 · vitamin E · young smokers with a history of less than 5 pack-years | 400 IU | 8 weeks | — |
| Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study 2000 · d-alpha-tocopherol group · Subjects with mild hypercholesterolemia undergoing statin treatment | 700 mg | 90 days | — |
| Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers 2001 · alpha-tocopherol · Adult male normolipidemic chronic smokers | 400 IU | 2 years | — |
| Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients 2002 · 400 IU/day vitamin E · Adults with hypercholesterolemia; age range and sex not specified | 400 IU | 8 weeks | — |
| Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients 2002 · 800 IU/day vitamin E · Adults with hypercholesterolemia; age range and sex not specified | 800 IU | 8 weeks | — |
| Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial 2002 · vitamin E alone · nonsmokers | 400 IU | 60 days | — |
| Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men 2003 · Vitamin E, young men · Healthy men aged 26.4 ± 3.3 years | 1,000 IU | 12 weeks | — |
| Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men 2003 · Vitamin E, older men · Healthy men aged 71.1 ± 4.0 years | 1,000 IU | 12 weeks | — |
| Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study 2003 · Vitamin E treatment group · Children with biopsy-proven IgA nephropathy, weighing 30 kg as described in the abstract | 400 IU | 2 years | — |
| Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments 2003 · Vitamin E supplementation in simvastatin-treated patients · Patients with hypercholesterolemia receiving simvastatin | 400 IU | 26 weeks | — |
| Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments 2003 · Vitamin E supplementation in bezafibrate-treated patients · Patients with hypercholesterolemia receiving bezafibrate | 400 IU | 26 weeks | — |
| Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes 2004 · Vitamin E group · Patients with acute coronary syndromes; smoker subgroup results were reported | 400 IU | 26 weeks | — |
| Randomized, placebo-controlled pilot trial of the effects of alpha-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients 2004 · alpha-tocopherol treatment group · Melanoma outpatients; age and sex not specified | 1 g | 90 days | — |
| Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status 2004 · Vitamin E supplementation, study A · Men and women with rheumatoid arthritis, not taking oral anticoagulants | 1,000 IU | 12 weeks | — |
| Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status 2004 · Vitamin E supplementation, study B · Healthy men, not taking oral anticoagulants | 1,000 IU | 12 weeks | — |
| Effect of vitamin E on carotid artery elasticity and baroreflex gain in young, healthy adults 2004 · active treatment group · young, healthy adults | 700 IU | 30 days | — |
| Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial 2005 · group 2 · Clinically stable, non-diabetic adults on haemodialysis or peritoneal dialysis without manifest cardiovascular disease | 800 IU | 12 weeks | — |
| Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial 2005 · group 3 · Clinically stable, non-diabetic adults on haemodialysis or peritoneal dialysis without manifest cardiovascular disease | 800 IU | 12 weeks | — |
| Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease 2007 · RRR-α-tocopherol group · Adults aged 40–70 with stable coronary artery disease, receiving lipid-lowering medication | 1,200 IU | 2 years | — |
| Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome 2008 · AT (RRR) alone · Adults recruited from the community with at least three features of metabolic syndrome | 800 mg | 6 weeks | — |
| Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome 2008 · GT · Adults recruited from the community with at least three features of metabolic syndrome | 800 mg | 6 weeks | — |
| The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level 2008 · vitamin E capsule and placebo tablet · Adults aged 18 years or older; healthy nonsmokers without the listed excluded diseases | 800 IU | 60 days | — |
| Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease 2009 · Vitamin E (with or without orange and blackcurrant juice) · Patients with peripheral arterial disease; age and sex not specified | 15 mg | 4 weeks | — |
| [Study the effect of antioxidant vitamin E, vitamin C and beta-carotene supplement on erythrocyte functions in elderly person] 2008 · Group 5 · Adults aged 60–75 years; elderly participants | 5 mg | 16 weeks | — |
| Vitamin C treatment reduces elevated C-reactive protein 2009 · Vitamin E group · Healthy nonsmokers; adults, mean age 44 years; not restricted to elevated CRP | 800 IU | 60 days | — |
| Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis 2008 · group CE (CLAs and vitamin E) · Adults aged 19–69 with active rheumatoid arthritis | 400 mg | 12 weeks | — |
| Investigation of the effects of oral administration of vitamin E and beta-carotene on the chemiluminescence responses and the frequency of sister chromatid exchanges in circulating leukocytes from cigarette smokers 1990 · Group 1 · Asymptomatic cigarette smokers; age and sex not specified | 900 IU | 6 weeks | — |
| Effects of hemodialysis and vitamin E supplementation on low-density lipoprotein oxidizability in end-stage renal failure 2013 · vitamin E supplementation · Adults with end-stage renal failure receiving chronic hemodialysis; age range and sex not stated | 800 IU | 12 weeks | — |
| α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial 2014 · α-tocopherol · Children aged 7–15 years, both sexes, with Down syndrome | 400 IU | 120 days | — |
| Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress 2016 · vitamin E · men aged 55 years or older (50 or older for African Americans) who were current smokers without COPD | 400 IU | 3 years | — |
| Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial 2018 · high TT · Postmenopausal women with osteopenia | 860 mg | 12 weeks | — |
| Effects of High-dose Vitamin E Supplementation on Markers of Cardiometabolic Risk and Oxidative Stress in Patients with Diabetic Nephropathy: a Randomized Double-blinded Controlled Trial 2018 · vitamin E supplement group · Patients with diabetic nephropathy | 800 IU | 12 weeks | — |
| Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment 2018 · vitamin E · Patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) | 400 IU | 52 weeks | — |
| Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment 2018 · spironolactone plus vitamin E · Patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) | 400 IU | 52 weeks | — |
| Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial 2019 · vitamin E 400 IU/day · Adults aged 18–65 with nonalcoholic fatty liver disease | 400 IU | 90 days | — |
| Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial 2019 · vitamin E · Patients with type 2 diabetes and biopsy-proven nonalcoholic steatohepatitis | 800 IU | 548 days | — |
| Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial 2019 · vitamin E plus pioglitazone · Patients with type 2 diabetes and biopsy-proven nonalcoholic steatohepatitis | 800 IU | 548 days | — |
| Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function 2021 · vitamin E treatment · Overweight subjects with elevated alanine aminotransferase (ALT) | 800 IU | 8 weeks | — |
| Derepression of glomerular filtration, renal blood flow and antioxidant defence in patients with type 2 diabetes at high-risk of cardiorenal disease 2020 · vitamin E · Adults with type 2 diabetes and hypertension and/or microalbuminuria, eGFR >45 mL/min/1.73 m²; non-Caucasian or Caucasian | 400 IU | 1 year | — |
| A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients 2021 · group 1 (Vitamin E) · Egyptian patients with non-alcoholic steatohepatitis (age and sex not specified) | 800 mg | 90 days | — |
| Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM 1995 · vitamin E · men aged 50–70 with non-insulin-dependent diabetes mellitus (NIDDM) and HbA1c 6–10% | 1,600 IU | 10 weeks | — |
| Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group 1995 · selegiline-placebo and active tocopherol · Adults with early, mild, untreated Parkinson's disease | 2,000 IU | — | — |
| Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group 1995 · active selegiline hydrochloride and active tocopherol · Adults with early, mild, untreated Parkinson's disease | 2,000 IU | — | — |
| The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans 1994 · vitamin E · Hypercholesterolaemic patients already receiving simvastatin | 400 IU | 8 weeks | — |
| The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients 1994 · vitamin E group · Heart transplant recipients; age and sex not reported | 500 IU | 60 days | — |
| Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation 1993 · alpha-tocopherol only · adult male subjects; age and health condition not specified | 800 IU | 90 days | — |
| Comparison of supplementation of RRR-alpha-tocopherol and racemic alpha-tocopherol in humans. Effects on lipid levels and lipoprotein susceptibility to oxidation 1993 · RRR-alpha-tocopherol group · Men and women; ages and health status not specified | 1.6 g | 8 weeks | — |
| Comparison of supplementation of RRR-alpha-tocopherol and racemic alpha-tocopherol in humans. Effects on lipid levels and lipoprotein susceptibility to oxidation 1993 · Racemic alpha-tocopherol group · Men and women; ages and health status not specified | 1.6 g | 8 weeks | — |
| RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus 1996 · RRR-alpha-tocopherol-supplemented group · People with insulin-dependent or non-insulin-dependent diabetes mellitus, without evidence of vascular disease | 1.63 g | 8 weeks | — |
| What dose of vitamin E is required to reduce susceptibility of LDL to oxidation? 1996 · 500 IU/day vitamin E · Healthy volunteers | 500 IU | 6 weeks | — |
| What dose of vitamin E is required to reduce susceptibility of LDL to oxidation? 1996 · 1000 IU/day vitamin E · Healthy volunteers | 1,000 IU | 6 weeks | — |
| What dose of vitamin E is required to reduce susceptibility of LDL to oxidation? 1996 · 1500 IU/day vitamin E · Healthy volunteers | 1,500 IU | 6 weeks | — |
| Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans 1997 · Olive oil with vitamin E · Healthy men; age not stated | 900 IU | 6 weeks | — |
| Vitamin E supplementation in elderly lowers the oxidation rate of linoleic acid in LDL 1997 · vitamin E group · Apparently healthy Dutch adults aged 67–85 years | 100 IU | 90 days | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · RRR-AT 100 IU/d · Healthy people; age and sex not specified | 100 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · RRR-AT 200 IU/d · Healthy people; age and sex not specified | 200 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · RRR-AT 400 IU/d · Healthy people; age and sex not specified | 400 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · RRR-AT 800 IU/d · Healthy people; age and sex not specified | 800 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · all-rac-AT 100 IU/d · Healthy people; age and sex not specified | 100 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · all-rac-AT 200 IU/d · Healthy people; age and sex not specified | 200 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · all-rac-AT 400 IU/d · Healthy people; age and sex not specified | 400 IU | 8 weeks | — |
| Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation 1997 · all-rac-AT 800 IU/d · Healthy people; age and sex not specified | 800 IU | 8 weeks | — |
| Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance 1997 · vitamin E group · Normal volunteers and patients with ischemic heart disease; ages and sex not reported | 600 mg | 6 days | — |
| Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo 1998 · vitamin E · Participants in the second study; sex, age range, and health status not reported | 1,000 IU | 2 weeks | — |
| Vitamin E levels during early iron supplementation in preterm infants 2009 · 2-week group · Preterm infants assigned to start iron supplementation at 2 weeks of age | 25 IU | 6 weeks | 62 |
| Vitamin E levels during early iron supplementation in preterm infants 2009 · 4-week group · Preterm infants assigned to start iron supplementation at 4 weeks of age | 25 IU | 4 weeks | 54 |
| Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes 2000 · nonsmokers receiving vitamin cocktail · Male nonsmokers selected for low fruit and vegetable intake | 31 mg | 90 days | 38 |
| Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes 2000 · smokers receiving vitamin cocktail · Male smokers selected for low fruit and vegetable intake | 31 mg | 90 days | 37 |
| Antioxidant supplementation enhances antioxidant capacity and mitigates oxidative damage following acute ischaemic stroke 2005 · Treatment group · Acute ischaemic stroke patients treated within 12 hours of symptom onset | 800 IU | 2 weeks | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 800 IU | 2 weeks | 24 |
| Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners 1998 · antioxidant cocktail · Moderately trained male marathon runners | 13.5 mg | 3 weeks | 18 |
| Supplementation with antioxidants prior to bone marrow transplantation 1997 · BMT(+) · Bone marrow transplant patients receiving conditioning therapy | 825 mg | 3 weeks | 16 |
| Effect of Vitamin E With Therapeutic Iron Supplementation on Iron Repletion and Gut Microbiome in US Iron Deficient Infants and Toddlers 2016 · iron + vitamin E (Fe + E group) · Infants and toddlers aged 9–24 months with iron deficiency or iron deficiency anemia | 18 mg | 8 weeks | 15 |
| Combined effect of antioxidant supplementation and resistance training on oxidative stress markers, muscle and body composition in an elderly population 2011 · AS (vitamin C and E supplementation) · Healthy sedentary adults aged 59–73 years, men and women | 400 IU | 26 weeks | 14 |
| Combined effect of antioxidant supplementation and resistance training on oxidative stress markers, muscle and body composition in an elderly population 2011 · AS + RT (vitamin C and E supplementation combined with resistance training) · Healthy sedentary adults aged 59–73 years, men and women | 400 IU | 26 weeks | 14 |
| The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C 2009 · low dose vitamins · Adults with well-controlled, non-insulin-requiring type 2 diabetes; men and women, mean age 53 years | 200 IU | 2 weeks | 12 |
| The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C 2009 · medium dose vitamins · Adults with well-controlled, non-insulin-requiring type 2 diabetes; men and women, mean age 53 years | 400 IU | 2 weeks | 12 |
| The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C 2009 · high dose vitamins · Adults with well-controlled, non-insulin-requiring type 2 diabetes; men and women, mean age 53 years | 800 IU | 2 weeks | 12 |
| Noncompetitive plasma biokinetics of deuterium-labeled natural and synthetic alpha-tocopherol in healthy men with an apoE4 genotype 2005 · RRR-alpha-tocopheryl acetate treatment · Healthy men with the apoE4 genotype | 400 mg | 4 weeks | 10 |
| Noncompetitive plasma biokinetics of deuterium-labeled natural and synthetic alpha-tocopherol in healthy men with an apoE4 genotype 2005 · all-rac-alpha-tocopheryl acetate treatment · Healthy men with the apoE4 genotype | 400 mg | 4 weeks | 10 |
| Effect of the main dietary antioxidants (carotenoids, gamma-tocopherol, polyphenols, and vitamin C) on alpha-tocopherol absorption 2007 · Meal containing 18 mg lutein · Healthy men; age not reported | 24 mg | 1 day | 8 |
| Effect of the main dietary antioxidants (carotenoids, gamma-tocopherol, polyphenols, and vitamin C) on alpha-tocopherol absorption 2007 · Meal containing 36 mg lutein · Healthy men; age not reported | 24 mg | 1 day | 8 |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · evening primrose oil (EPO) · Healthy subjects; age and sex not specified | 205 mg | 12 weeks | — |
| Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study 2000 · Q10 and d-alpha-tocopherol group · Subjects with mild hypercholesterolemia undergoing statin treatment | 700 mg | 90 days | — |
| Accumulation and interactions of beta-carotene and alpha-tocopherol in patients with adenomatous polyps 2002 · combination BC/VE · Volunteers with colonic adenomatous polyps; age and sex not reported | 400 IU | 43 days | — |
| Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function 2003 · group A [low dose of supplement] · Patients with cystic fibrosis; age and sex not specified | 10 mg | 8 weeks | — |
| Effects of maternal antioxidant supplementation on maternal and fetal antioxidant levels: a randomized, double-blind study 2003 · Supplemented women · Pregnant women starting supplementation at 35 weeks' gestation | 400 IU | — | — |
| Differential response of plasma and immune cell's vitamin E levels to physical activity and antioxidant vitamin supplementation 2005 · supplemented group · trained male amateur runners aged 32–36 years who participated in a half-marathon | 50 mg | 30 days | — |
| Fat-soluble vitamins in cystic fibrosis and pancreatic insufficiency: efficacy of a nutrition intervention 2014 · LXS group, ages 5.0 to 11.9 years · Children aged 5.0–11.9 years with cystic fibrosis, pancreatic insufficiency, and mild to moderate lung disease | 9.6 mg | 1 year | — |
| Fat-soluble vitamins in cystic fibrosis and pancreatic insufficiency: efficacy of a nutrition intervention 2014 · LXS group, ages 12.0 to 17.9 years · Children and adolescents aged 12.0–17.9 years with cystic fibrosis, pancreatic insufficiency, and mild to moderate lung disease | 14.4 mg | 1 year | — |
| Antioxidant vitamin supplementation prevents oxidative stress but does not enhance performance in young football athletes 2019 · antioxidant-supplemented · Young football athletes; age and sex not specified | 400 IU | 15 days | — |
| Antioxidants, Helicobacter pylori and stomach cancer in Venezuela 1996 · Treatment 1 · People with precancerous stomach lesions, including chronic gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia; age and sex not specified | 600 mg | 7 days | — |
| Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network 1996 · V (vitamins) · Elderly nursing-home residents aged 65–103 years who were long-term hospitalized | 15 mg | 26 weeks | — |
| Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters 1997 · vitamin group · Hospitalized adults older than 65 years; baseline vitamin C deficiency was common | 15 mg | 2 years | — |
| Effects of trace element and/or vitamin supplementation on vitamin and mineral status, free radical metabolism and immunological markers in elderly long term-hospitalized subjects. Geriatric Network MIN. VIT. AOX 1997 · vitamins · Institutionalized elderly subjects in long-term hospital or nursing-home care | 15 mg | 1 year | — |
| The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes 2004 · group MV · Adults with type 2 diabetes; age and sex not reported | 150 mg | 90 days | 17 |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 15 mg | 165 days | 749 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 40 mg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 40 mg | 24 weeks | 201 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 15 mg | — | 176 |
| Multiple Micronutrient Powder Reduces Vitamin E Deficiency in Brazilian Children: A Pragmatic, Controlled Clinical Trial 2019 · intervention group · Children aged 6–9 months at the start of the study, male or female, attending primary health care centers in Goiânia, Brazil | 5 mg | 90 days | 107 |
| Proliferative changes in the bronchial epithelium of former smokers treated with retinoids 2007 · 13-cis-RA and α-tocopherol group · Former smokers with a history of at least 20 pack-years who had stopped smoking at least 12 months before study entry; adult age range not stated | 1,200 IU | 90 days | 77 |
| Comparison of L-Carnitine vs. Coq10 and Vitamin E for idiopathic male infertility: a randomized controlled trial 2022 · control group · men with asthenozoospermia and teratozoospermia | 300 mg | 90 days | 70 |
| Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 2019 · treated · Adults aged 18–80 with histologically diagnosed nonalcoholic fatty liver disease (NAFLD) | 30 mg | 26 weeks | 60 |
| Trace element supplementation in hemodialysis patients: a randomized controlled trial 2015 · medium dose · Adults aged 18 years or older on maintenance hemodialysis, with end-stage kidney disease | 250 IU | 180 days | 52 |
| [Effects of vitamins E, C and beta-carotene on DNA damage] 1999 · trial group · Healthy men aged 50–59 years | 280 mg | 20 weeks | 50 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 15 mg | 1 year | 50 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 100 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 100 mg | 5 weeks | 48 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 200 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 200 mg | 5 weeks | 48 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 400 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 400 mg | 5 weeks | 48 |
| Trace element supplementation in hemodialysis patients: a randomized controlled trial 2015 · low dose · Adults aged 18 years or older on maintenance hemodialysis, with end-stage kidney disease | 250 IU | 180 days | 47 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · type 2 diabetes group · Adults with early-stage, untreated type 2 diabetes | 300 g | 15 days | 46 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · impaired glucose tolerance group · Adults with impaired glucose tolerance | 300 g | 15 days | 46 |
| Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls 2005 · healthy control group · Healthy adults | 300 g | 15 days | 46 |
| Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial 2005 · vitamin E and vitamin C group · Patients with asymptomatic or mildly symptomatic moderate chronic degenerative aortic stenosis, with or without concomitant coronary artery disease; age and sex not reported | 400 IU | 26 weeks | 41 |
| Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults 2003 · spread A · healthy adults | 43 mg | 11 weeks | 35 |
| Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults 2003 · spread B · healthy adults | 111 mg | 11 weeks | 35 |
| The effect of selenium and vitamin E supplementation on anti-Mullerian hormone and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial 2021 · treatment group · Infertile women with occult premature ovarian insufficiency | 400 IU | 90 days | 35 |
| Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up 2015 · Group A (antioxidant dietary supplementation) · Adults aged 40–79 with type 2 diabetes and mild or moderate nonproliferative diabetic retinopathy | 30 mg | 26 weeks | 34 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome 2017 · omega-3 fatty acids and vitamin E · Women aged 18–40 years with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 400 IU | 12 weeks | 34 |
| The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids and vitamin E co-supplementation · Women aged 18–40 years with polycystic ovary syndrome | 400 IU | 12 weeks | 34 |
| Omega-3 and vitamin E co-supplementation can improve antioxidant markers in obese/overweight women with polycystic ovary syndrome 2020 · omega-3 plus vitamin E group · Women with polycystic ovary syndrome and BMI >25 who were overweight or obese | 400 IU | 8 weeks | 32 |
| Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients 2001 · combined vitamin C and E treatment · Adults with type 2 diabetes and persistent micro/macroalbuminuria (urinary albumin excretion rate 30–300 mg/24 h) | 680 IU | 4 weeks | 30 |
| A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes 2016 · omega-3 fatty acids plus vitamin E group · Women with gestational diabetes who were not taking oral hypoglycemic agents | 400 IU | 6 weeks | 30 |
| A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes 2017 · omega-3 fatty acids plus vitamin E · Women with gestational diabetes who were not taking oral hypoglycemic agents | 400 IU | 6 weeks | 30 |
| The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes 2018 · magnesium plus vitamin E group · Women aged 18–40 with gestational diabetes, non-diabetic before pregnancy | 400 IU | 6 weeks | 30 |
| The Effect of Combined Vitamin C and Vitamin E Supplementation on Oxidative Stress Markers in Women with Endometriosis: A Randomized, Triple-Blind Placebo-Controlled Clinical Trial 2021 · Group A · Women aged 15–45 with pelvic pain and laparoscopically confirmed stage 1–3 endometriosis | 800 IU | 8 weeks | 30 |
| Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment 2005 · vitamin E plus vitamin C combination · Patients with histologically proven fatty liver disease and chronically elevated alanine aminotransferase despite a three-month reducing diet; age and sex distribution not stated | 600 IU | 26 weeks | 28 |
| Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids plus vitamin E · Patients with fibrocystic breast disease | 400 mg | 12 weeks | 28 |
| The effect of zinc and vitamin E cosupplementation on metabolic status and its related gene expression in patients with gestational diabetes 2019 · Zinc gluconate plus vitamin E · Women aged 18–40 with gestational diabetes mellitus | 400 IU | 6 weeks | 27 |
| High 15-F2t-Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant Therapy 2015 · supplemented group · Adults aged 20 years or older with a previous history of nonmelanoma skin cancer treated by surgery | 400 IU | 60 days | 26 |
| Effect of Vitamin E Supplement on Bone Turnover Markers in Postmenopausal Osteopenic Women: A Double-Blind, Randomized, Placebo-Controlled Trial 2021 · study group · Postmenopausal women over 45 with osteopenia | 400 IU | 12 weeks | 26 |
| Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects 1998 · vitamin group · HIV-positive patients; age and sex not specified | 800 IU | 90 days | 26 |
| The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial 2011 · 800 mg α-tocopherol + 600 mg LA · Patients with type 2 diabetes mellitus; age and sex not reported | 800 mg | 120 days | 25 |
| Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial 2020 · PPE + Vit E · Hemodialysis patients; age and sex ranges not reported | 400 IU | 8 weeks | 25 |
| Fat-Soluble Vitamin Supplementation Using Liposomes, Cyclodextrins, or Medium-Chain Triglycerides in Cystic Fibrosis: A Randomized Controlled Trial 2021 · Liposomal group · Patients aged 16–55 years with pancreatic-insufficient cystic fibrosis | 200 IU | 90 days | 25 |
| Fat-Soluble Vitamin Supplementation Using Liposomes, Cyclodextrins, or Medium-Chain Triglycerides in Cystic Fibrosis: A Randomized Controlled Trial 2021 · MCT group · Patients aged 16–55 years with pancreatic-insufficient cystic fibrosis | 200 IU | 90 days | 25 |
| Soy isoflavones improve bone metabolism in postmenopausal Japanese women 2004 · V · Women; a subgroup of the study participants was postmenopausal | 5 mg | 4 weeks | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 800 IU | 2 weeks | 24 |
| Antioxidants restore protoporphyrinogen oxidase in variegate porphyria patients 2013 · vitamins E and C treatment phase · 12 women with variegate porphyria and 12 control women | 50 mg | 26 weeks | 24 |
| Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes 2003 · Fish oil group · Adults with type 2 diabetes | 53.6 mg | 8 weeks | 23 |
| [Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases] 2012 · Experimental cases with asthenospermia · Infertile men with asthenospermia | 300 mg | 90 days | 22 |
| Antioxidant vitamins and low-density-lipoprotein oxidation 1993 · antioxidant supplementation · Adults; ages and health conditions not stated | 200 mg | 26 weeks | 22 |
| Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes 2003 · Corn oil group · Adults with type 2 diabetes | 53.6 mg | 8 weeks | 21 |
| [A randomized single-blind trial of the effects of vitamins C and E in familial hypercholesterolemia] 2006 · vitamin therapy group · Girls and boys aged 2–18 years with heterozygous familial hypercholesterolemia and LDL-cholesterol above 160 mg/dl | 400 IU | 1 year | 21 |
| Prospective analysis of serum carotenoids, vitamin A, and tocopherols in adults with short bowel syndrome undergoing intestinal rehabilitation 2009 · All subjects (shared oral multivitamin-mineral supplementation) · Adults with severe short bowel syndrome dependent on parenteral nutrition | 90 mg | 11 weeks | 21 |
| Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy 2024 · Vitamin C and E group · Patients aged over 11 and under 80 with stage II–IV head and neck cancer receiving cisplatin chemotherapy; males and females | 250 IU | 3 weeks | 21 |
| Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial 1992 · active treatment · Patients with recurrent non-gallstone pancreatitis | 270 IU | 10 weeks | 20 |
| Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis 2011 · Group 3 · Adults aged 18–60 with end-stage renal disease receiving hemodialysis | 400 IU | 3 weeks | 20 |
| Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease 2016 · Group 2 (OE) · Male patients with coronary artery disease; age range not reported | 400 IU | 60 days | 20 |
| Redox-regulation of haemostasis in hypoxic exercising humans: a randomised double-blind placebo-controlled antioxidant study 2018 · antioxidant group · Healthy males | 900 IU | 8 weeks | 20 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2019 · omega-3 fatty acids plus vitamin E · Patients with Parkinson's disease; age range and sex not reported | 400 IU | 12 weeks | 20 |
| Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial 2002 · vitamin group · cardiac transplant recipients 0–2 years after transplantation | 800 IU | 1 year | 19 |
| Influence of vitamin C and E supplementation on oxidative stress induced by hyperbaric oxygen in healthy men 2006 · Daily vitamin C and vitamin E supplementation · Healthy men | 272 IU | 4 weeks | 19 |
| Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial 2016 · Intervention group · Adults aged 20–50 years with obesity (BMI 30–40 kg/m²) and non-alcoholic fatty liver disease, taking vitamin E as routine treatment | 400 IU | 8 weeks | 19 |
| Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes 2005 · group V · Patients with type 2 diabetes; age range and sex not specified | 100 IU | 90 days | 18 |
| Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress 1999 · LA alone for 2 months, followed by LA and AT combination for 2 months · Healthy adults; age and sex not specified | 400 IU | 120 days | 16 |
| Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress 1999 · AT alone for 2 months, followed by LA and AT combination for 2 months · Healthy adults; age and sex not specified | 400 IU | 120 days | 15 |
| Oxidative stress response to aerobic exercise: comparison of antioxidant supplements 2006 · V treatment · Aerobically trained men and women | 400 IU | 2 weeks | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 400 mg | 1 day | 15 |
| Antioxidant Supplementation Protects Elite Athlete Muscle Integrity During Submaximal Training 2022 · antioxidant supplementation (AS) · Elite-level endurance athletes | 1,000 IU | 6 weeks | 15 |
| Antioxidant supplementation enhances neutrophil oxidative burst in trained runners following prolonged exercise 2003 · antioxidant vitamin supplement · Healthy trained endurance runners; 6 men and 6 women, mean age 30.1 years | 90 mg | 7 days | 12 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 72 mg | 3 weeks | 12 |
| Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation 1993 · combined antioxidant therapy · adult male subjects; age and health condition not specified | 800 IU | 90 days | 12 |
| Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin 2007 · zinc group · Patients with chronic hepatitis C receiving pegylated interferon alpha-2b and ribavirin therapy | 300 mg | 48 weeks | 11 |
| Protective effect of alpha-tocopherol and L-ascorbic acid against the ischemic-reperfusion injury in patients during open-heart surgery 1991 · Group 2 · Adults undergoing cardiopulmonary bypass for treatment of cardiac disease; age and sex not reported | 2,000 IU | 1 day | 11 |
| Effects of supplementation of antioxidant vitamins and lipid peroxidation in critically ill patients 2013 · G2 · Critically ill patients; age and sex not reported | 400 mg | 8 days | 11 |
| Effect of nutrition intervention on antioxidant capacity and lipid peroxide in patients with bone marrow transplantation 2002 · experimental group · Bone marrow transplantation recipients; age and sex not reported | 600 mg | 15 days | 10 |
| Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients 2005 · antioxidant supplementation phase · renal transplant recipients taking cyclosporin A; age and sex not reported | 400 IU | 26 weeks | 10 |
| Sex differences in the inhibition of gamma-tocopherol metabolism by a single dose of dietary sesame oil in healthy subjects 2008 · Sesame oil muffin treatment · Healthy adult women and men; ages not stated | 100 mg | 1 day | 10 |
| Phototoxic lysis of erythrocytes from humans is reduced after oral intake of ascorbic acid and d-alpha-tocopherol 1997 · vitamins group · Human volunteers; age and sex not specified; no stated condition | 1,000 IU | 7 days | 10 |
| Combined antioxidant treatment effects on blood oxidative stress after eccentric exercise 2005 · antioxidant supplement · Women aged 19–31 years who were not resistance-trained, undergoing eccentric elbow-flexor exercise | 400 IU | 16 days | 9 |
| Total radical-trapping antioxidant potential (TRAP) of plasma: effects of supplementation of young healthy volunteers with large doses of alpha-tocopherol and ascorbic acid 1993 · Group 4, alpha-tocopherol and ascorbic acid · Young healthy adults; age range and sex not reported | 1 g | 4 weeks | 8 |
| Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle 2004 · Treatment · Young healthy men | 400 IU | 4 weeks | 7 |
| Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment 2003 · antioxidant supplementation · 11 antiphospholipid antibody-positive patients | 900 IU | 6 weeks | 6 |
| Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients 2005 · EPA group · Patients with chronic hepatitis C receiving interferon alpha-2b and ribavirin; age and sex not reported | 300 mg | 24 weeks | 5 |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 205 mg | 12 weeks | — |
| Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial 2001 · Selenium with alpha-tocopherol and zinc · Critically ill trauma patients, mean age 42 years, with severe multiple injury | 150 mg | 5 days | — |
| Effect of two years' supplementation with natural antioxidants on vitamin and trace element status biomarkers: preliminary data of the SU.VI.MAX study 2001 · Antioxidant supplementation group · Women aged 35–60 years and men aged 45–60 years in France, general population | 30 mg | 2 years | — |
| Diet supplementation with vitamin E, vitamin C and beta-carotene cocktail enhances basal neutrophil antioxidant enzymes in athletes 2002 · antioxidant-supplemented group · Sportsmen; age and health condition not specified | 500 mg | 90 days | — |
| Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial 2002 · vitamins C + E · nonsmokers | 400 IU | 60 days | — |
| Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function 2003 · group B [high dose of supplement] · Patients with cystic fibrosis; age and sex not specified | 200 mg | 8 weeks | — |
| Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial 2003 · vitamins E and C · Adults with stable, inactive or mildly active Crohn's disease and oxidative stress | 800 IU | 4 weeks | — |
| Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers 2003 · group B · Healthy smokers; age range and sex not reported | 400 IU | 4 weeks | — |
| Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers 2003 · group C · Healthy smokers; age range and sex not reported | 800 IU | 4 weeks | — |
| Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers 2003 · Vitamins before breakfast · 11 people with type 2 diabetes | 800 IU | 1 day | — |
| Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers 2003 · Vitamins before supper · 11 people with type 2 diabetes | 800 IU | 1 day | — |
| Changes in serum retinol, alpha-tocopherol, vitamin C, carotenoids, xinc and selenium after micronutrient supplementation during alcohol rehabilitation 2003 · micronutrient supplement group · Alcohol-dependent patients aged 20 to 60 years without severe liver disease, hospitalized for alcohol rehabilitation | 30 mg | 3 weeks | — |
| Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction 2003 · vitamin C and E · Patients with acute myocardial infarction; age and sex not specified | 600 mg | 2 weeks | — |
| Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers 2003 · group B · Healthy young chronic smokers; age and sex not specified | 400 IU | 4 weeks | — |
| Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers 2003 · group C · Healthy young chronic smokers; age and sex not specified | 800 IU | 4 weeks | — |
| Antioxidant diet supplementation influences blood iron status in endurance athletes 2004 · antioxidant supplemented · Amateur trained male endurance athletes | 500 mg | 90 days | — |
| Antioxidant supplementation and nasal inflammatory responses among young asthmatics exposed to high levels of ozone 2004 · vitamin supplement group · Children with asthma living in Mexico City | 50 mg | 120 days | — |
| Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA adducts and potential cancer risk in female smokers 2005 · antioxidant vitamin supplementation · smokers who smoked at least 10 cigarettes per day and had serum cotinine of at least 25 ng/mL; both men and women enrolled | 400 IU | 456 days | — |
| Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study 2005 · vitamin-treated group · Patients with systemic lupus erythematosus (SLE); age and sex not stated | 800 IU | 12 weeks | — |
| Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment 2005 · antioxidant treatment group · Men with unexplained infertility and at least 15% DNA-fragmented spermatozoa in the ejaculate | 1 g | 60 days | — |
| Response of blood cell antioxidant enzyme defences to antioxidant diet supplementation and to intense exercise 2006 · antioxidant supplemented · Amateur trained male athletes; age and health condition not specified | 500 mg | 90 days | — |
| Vitamin E isoform-specific inhibition of the exercise-induced heat shock protein 72 expression in humans 2006 · CEalpha · Young men | 400 IU | 4 weeks | — |
| Vitamin E isoform-specific inhibition of the exercise-induced heat shock protein 72 expression in humans 2006 · CEalphagamma · Young men | 420 IU | 4 weeks | — |
| A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins 2006 · micronutrient supplementation · Disease-free people in a rural Chinese population; age and sex not specified | 200 IU | 2666 days | — |
| Antioxidant supplementation lowers exercise-induced oxidative stress in young overweight adults 2006 · overweight adults receiving antioxidant treatment · overweight adults aged 18–30 years | 800 IU | 8 weeks | — |
| Antioxidant supplementation lowers exercise-induced oxidative stress in young overweight adults 2006 · normal-weight adults receiving antioxidant treatment · normal-weight adults aged 18–30 years | 800 IU | 8 weeks | — |
| Multivitamin-mineral supplementation prevents lipid peroxidation during "the Marathon des Sables" 2007 · Supplemented group · Athletes participating in the Marathon des Sables; age and sex not specified | 24 mg | 4 weeks | — |
| Antioxidant diet supplementation enhances aerobic performance in amateur sportsmen 2007 · antioxidant-supplemented group · Amateur male athletes; age and health condition not stated | 500 mg | 90 days | — |
| Effect of vitamin supplementation on breast milk concentrations of retinol, carotenoids and tocopherols in HIV-infected Tanzanian women 2009 · multivitamins without vitamin A and β-carotene (MV) · HIV-infected pregnant women enrolled at 12–27 weeks of gestation in Dar es Salaam, Tanzania; women breastfeeding postpartum | 30 mg | — | — |
| Effect of vitamin supplementation on breast milk concentrations of retinol, carotenoids and tocopherols in HIV-infected Tanzanian women 2009 · multivitamins including vitamin A and β-carotene · HIV-infected pregnant women enrolled at 12–27 weeks of gestation in Dar es Salaam, Tanzania; women breastfeeding postpartum | 30 mg | — | — |
| Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects 2007 · Supplement group, G1 · Men and women aged 19–65 years with hypercholesterolemia (cholesterol >230 mg/dL) | 30 mg | 4 weeks | — |
| Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects 2007 · Supplement group, G2 · Men and women aged 19–65 years with hypercholesterolemia (cholesterol >230 mg/dL) | 30 mg | 4 weeks | — |
| Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects 2007 · Supplement group, G3 · Men and women aged 19–65 years with hypercholesterolemia (cholesterol >230 mg/dL) | 30 mg | 12 weeks | — |
| Gender comparisons of exercise-induced oxidative stress: influence of antioxidant supplementation 2007 · antioxidant (A) · Men and women who ran for 30 minutes at 80% VO2 max; ages and health conditions not stated | 400 IU | 2 weeks | — |
| Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome 2008 · AT+GT combination · Adults recruited from the community with at least three features of metabolic syndrome | 1.6 g | 6 weeks | — |
| Inflammatory response to a high-fat, low-carbohydrate weight loss diet: effect of antioxidants 2008 · antioxidant supplement (AS) · Overweight adults with BMI >27 kg/m²; age and sex not specified | 800 IU | 7 days | — |
| Influence of an antioxidant vitamin-enriched drink on pre- and post-exercise lymphocyte antioxidant system 2008 · antioxidant supplementation · Male amateur trained runners aged 32–36 years | 50 mg | 30 days | — |
| [Study the effect of antioxidant vitamin E, vitamin C and beta-carotene supplement on erythrocyte functions in elderly person] 2008 · Group 1 · Adults aged 60–75 years; elderly participants | 200 mg | 16 weeks | — |
| [Study the effect of antioxidant vitamin E, vitamin C and beta-carotene supplement on erythrocyte functions in elderly person] 2008 · Group 2 · Adults aged 60–75 years; elderly participants | 200 mg | 16 weeks | — |
| [Study the effect of antioxidant vitamin E, vitamin C and beta-carotene supplement on erythrocyte functions in elderly person] 2008 · Group 3 · Adults aged 60–75 years; elderly participants | 200 mg | 16 weeks | — |
| Effects of antioxidant supplementation on insulin sensitivity, endothelial adhesion molecules, and oxidative stress in normal-weight and overweight young adults 2009 · Normal-weight antioxidant-treated (N-AOX) · Apparently healthy men and women aged 18–30 years with BMI <25 kg/m² | 800 IU | 8 weeks | — |
| Effects of antioxidant supplementation on insulin sensitivity, endothelial adhesion molecules, and oxidative stress in normal-weight and overweight young adults 2009 · Overweight antioxidant-treated (O-AOX) · Apparently healthy men and women aged 18–30 years with BMI ≥25 kg/m² | 800 IU | 8 weeks | — |
| Cytokine response to vitamin E supplementation is dependent on pre-supplementation cytokine levels 2008 · vitamin E · Adults aged 66–100 living in long-term care facilities | 200 IU | 1 year | — |
| Serum vaspin concentrations are decreased after exercise-induced oxidative stress 2010 · antioxidant supplementation · healthy young men after a standardized 4-week physical training program | 400 IU | 4 weeks | — |
| Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation 2011 · n-3 PUFA plus antioxidant vitamins · Either-sex patients undergoing on-pump cardiac surgery | 400 IU | — | — |
| Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation 2011 · Antioxidant vitamins C and E without n-3 PUFA · Either-sex patients undergoing on-pump cardiac surgery | 400 IU | — | — |
| Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures 2012 · E/C/ALA · Adults aged 50–85 with probable Alzheimer disease and MMSE scores of 16 or more | 800 IU | 16 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · ORAL MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · ORAL CN-MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| Prevention of neutrophil protein oxidation with vitamins C and E diet supplementation without affecting the adaptive response to exercise 2013 · antioxidant supplementation · Trained male amateur runners | 50 mg | 30 days | — |
| Modulation of (Na,K)-ATPase activity by membrane fatty acid composition: therapeutic implications in human hypertension 2014 · vitamin C + E · Men with essential hypertension; age range not reported | 400 IU | 8 weeks | — |
| Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial 2014 · CaDEA · Children aged approximately 8 years | 12 IU | 12 weeks | — |
| Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents 2014 · antioxidant supplementation · Overweight or obese children and adolescents; mean age 12.7 ± 1.5 years | 400 IU | 120 days | — |
| Antioxidants may Attenuate Plasma Erythropoietin Decline after Hyperbaric Oxygen Diving 2015 · vitamin group · healthy male police task force divers exposed to repeated hyperbaric oxygen diving | 600 IU | 3 days | — |
| Vitamin C and E supplementation prevents some of the cellular adaptations to endurance-training in humans 2015 · antioxidant group · healthy young males | 400 IU | 8 weeks | — |
| Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress 2016 · vitamin E+selenium · men aged 55 years or older (50 or older for African Americans) who were current smokers without COPD | 400 IU | 3 years | — |
| Derepression of glomerular filtration, renal blood flow and antioxidant defence in patients with type 2 diabetes at high-risk of cardiorenal disease 2020 · vitamin E and selenium · Adults with type 2 diabetes and hypertension and/or microalbuminuria, eGFR >45 mL/min/1.73 m²; non-Caucasian or Caucasian | 400 IU | 1 year | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants only · Adults aged 55–80 with early or more advanced age-related macular degeneration | 400 IU | 5 years | — |
| Lipid peroxidation and antioxidative vitamins under extreme endurance stress 1994 · Supplemented group · Trained long-distance runners; age and sex not reported | 400 IU | 32 days | — |
| Effects of an antioxidant vitamin mixture on lipid peroxidation at rest and postexercise 1993 · antioxidant vitamin group · Young healthy males, mean age 25.0 years | 592 mg | 6 weeks | — |
| Antioxidants, Helicobacter pylori and stomach cancer in Venezuela 1996 · Treatment 2 · People with precancerous stomach lesions, including chronic gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia; age and sex not specified | 75 mg | 7 days | — |
| Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network 1996 · VT (vitamins associated with trace elements) · Elderly nursing-home residents aged 65–103 years who were long-term hospitalized | 15 mg | 26 weeks | — |
| Enhanced plasma level of lipid peroxidation in Iranians could be improved by antioxidants supplementation 1997 · beta-carotene plus alpha-tocopherol · Male medical students; age not reported; no condition reported | 400 IU | 10 weeks | — |
| Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans 1997 · Menhaden oil with vitamin E · Healthy men; age not stated | 900 IU | 6 weeks | — |
| Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease 1997 · mid-dose · Patients with established cardiovascular disease | 400 IU | 12 weeks | — |
| Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease 1997 · high dose · Patients with established cardiovascular disease | 800 IU | 12 weeks | — |
| Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters 1997 · mineral and vitamin group · Hospitalized adults older than 65 years; baseline deficiencies of vitamin C, zinc and selenium were common | 15 mg | 2 years | — |
| Effects of trace element and/or vitamin supplementation on vitamin and mineral status, free radical metabolism and immunological markers in elderly long term-hospitalized subjects. Geriatric Network MIN. VIT. AOX 1997 · trace elements associated with vitamins · Institutionalized elderly subjects in long-term hospital or nursing-home care | 15 mg | 1 year | — |
| Effects of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects 1998 · supplementation group · Adult men aged 45–60 years and women aged 35–60 years | 30 mg | 26 weeks | — |
| Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers 1998 · antioxidants without n-3 fatty acids · adult male smokers with hyperlipidaemia | 75 mg | 6 weeks | — |
| Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3) 1996 · intervention group · Patients with suspected acute myocardial infarction; age and sex not stated | 400 mg | 4 weeks | 63 |
| Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk 2004 · antioxidant-supplemented group · Middle-aged men: myocardial infarction survivors younger than 50 and healthy controls | 100 mg | 12 weeks | 53 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 300 mg | 2 years | 47 |
| [Effect of multiple micronutrients supplementation on anti-oxidative activity and oxidized DNA damage of lymphocytes in children] 2005 · supplement group · Chinese children aged 9–11 years, described as healthy and living in a rural area | 100 mg | 8 weeks | 41 |
| Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status 1991 · antioxidant-supplemented men · Men with low antioxidant status | 300 mg | 150 days | 39 |
| Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome 2006 · test group · Patients with metabolic syndrome; age and sex not specified | 7.5 mg | 90 days | 36 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 30 mg | 90 days | 30 |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG1 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 45 mg | 12 weeks | 30 |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG2 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 90 mg | 6 weeks | 30 |
| Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study 2022 · 4Nutri group · Young, healthy participants; age range and sex not stated | 3.29 mg | 3 weeks | 20 |
| Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial 1994 · supplemented group · Healthy men aged 30–58 years who smoked 15–40 cigarettes per day | 200 mg | 90 days | 20 |
| Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes 2005 · group MV · Patients with type 2 diabetes; age range and sex not specified | 100 IU | 90 days | 17 |
| Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia 2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia) | 120 mg | 30 days | 16 |
| Effect of antioxidant supplementation on urine and blood markers of oxidative stress during extended moderate-altitude training 1999 · antioxidant supplement (S) group · US Marine Corps volunteers undergoing 14 days of winter training at approximately 2700 m | 400 IU | 2 weeks | — |
| Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation 2004 · antioxidant mixture · Healthy adult men and women who were active or passive smokers | 794 mg | 60 days | — |
| Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX Study 2005 · antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 30 mg | 2738 days | — |
| Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration 2007 · antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration | 400 IU | 2433 days | — |
| Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial 2010 · antioxidant micronutrient combination · Patients with a history of sporadic colorectal adenoma; age and sex not specified | 800 mg | 120 days | — |
| Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise 2011 · LCPUFA plus antioxidant mixture · Judoists; age and sex not reported; no diagnosed condition stated | 30 mg | 6 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · COMBINED MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| New chitin complexes and their anti-aging activity from inside out 2012 · COMBINED CN-MEB · Healthy women aged 22–45 with signs of photoaging | 3.2 mg | 12 weeks | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 400 IU | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene and with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | 5 years | — |
| Response of hypercholesterolemic subjects to administration of tocotrienols 1995 · Palmvitee group · Hypercholesterolemic subjects; age and sex not specified | 260 mg | 4 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · antioxidants · male smokers with combined hyperlipidemia | 75 mg | 6 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia | 75 mg | 6 weeks | — |
| Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers 1998 · n-3 fatty acids with antioxidants · adult male smokers with hyperlipidaemia | 75 mg | 6 weeks | — |
| Does combined antioxidant vitamin supplementation blunt repeated bout effect? 2015 · supplement (S) group · moderately trained males | 400 IU | 2 weeks | — |
| [L-carnitine improves sperm acrosin activity in male infertility patients] 2018 · Control group · Male infertility patients with low sperm acrosin activity; age not reported | 300 mg | 90 days | 60 |
| Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults 2003 · spread C · healthy adults | 1.3 mg | 11 weeks | 35 |
| Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients 2016 · vitamin E + omega-3 fatty acids placebo · Chronic hemodialysis patients; age and sex not specified | 400 IU | 12 weeks | 30 |
| Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans 2002 · 25 mg/day TRF25 group · Hypercholesterolemic human subjects on the AHA Step-1 diet; age and sex not specified | 25 mg | 5 weeks | 18 |
| Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans 2002 · 50 mg/day TRF25 group · Hypercholesterolemic human subjects on the AHA Step-1 diet; age and sex not specified | 50 mg | 5 weeks | 18 |
| Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans 2002 · 200 mg/day TRF25 group · Hypercholesterolemic human subjects on the AHA Step-1 diet; age and sex not specified | 200 mg | 5 weeks | 18 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · Healthy subjects, 100 mg/day · 12 healthy subjects | 100 mg | 3 weeks | 12 |
| Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects 2006 · Healthy subjects, 200 mg/day · 12 healthy subjects | 200 mg | 3 weeks | 12 |
| Sex differences in the inhibition of gamma-tocopherol metabolism by a single dose of dietary sesame oil in healthy subjects 2008 · Corn oil muffin treatment · Healthy adult women and men; ages not stated | 100 mg | 1 day | 10 |
| Supplementation with antioxidants prior to bone marrow transplantation 1997 · Healthy control group · Healthy controls | 825 mg | 3 weeks | 10 |
| Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione 2002 · vitamin E · Patients who survived a recent myocardial infarction (<3 months) | 300 mg | — | — |
| Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione 2002 · n-3 PUFAs plus vitamin E · Patients who survived a recent myocardial infarction (<3 months) | 300 mg | — | — |
| Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration 2007 · antioxidants · Adults aged 55–80 with age-related macular degeneration | 400 IU | 2433 days | — |
| Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk 2009 · β-carotene plus vitamin E group · Men aged 50–69 years in southwestern Finland who smoked at least five cigarettes per day | 50 mg | 2228 days | — |